Supplementary Figure 1 | Locus zoom plot of the p-values of association for 1 further genome-wide significant association when meta-analysing CHAREG EU's longevity GWAMA and LifeGen across both parents in cohorts of European Ancestry. By combining our discovery association analysis with a long-livedness GWAS, we found an association with longevity for rs1919453, between genes AKAP7 and EBP41L2, but had no further data with which to seek replication. In the absence of replication, it is unclear if this SNP is reliably associated with lifespan.



<u>Supplementary Figure 2 | Locus zoom plots for chromosome 2 region.</u> African mothers (**A**), African fathers (**B**), and Europeans with both parents combined (**C**). rs10198124 shows consistent association with lifespan in African fathers across cohorts, but no evidence in African mothers or Europeans of both ancestries. (**D**) The forest plot shows estimates of the hazard ratio for carrying 1 copy of the risk allele +/- 2 SE, for each cohort, i.e. observed father-child effect sizes were doubled. The apparent association with lifespan, in African fathers may be due to chance, as there are not even suggestive associations in African mothers or either European parent.



Supplementary Figure 3 | Locus Zoom plots of the Validated Candidate Loci.

GWAMA and LifeGen across both parents in cohorts of European Ancestry.







Supplementary Figure 4 | Meaningful genetic correlations (r_g) between and mortality and trait. Traits which genetically correlate with increased mortality are shown in red and those correlating with increased longevity are in green. 113 traits were tested but only statistically significant correlations (FDR < 5%) with $|r_g| > 0.15$ are shown. Traits that are similar are all shown, for completeness and to avoid selection bias. The remaining traits and the studies from which the displayed genetic correlations were sourced can be found in Supplementary Table 3. HOMA-IR; homeostatic model assessment of insulin resistance, SBP; systolic blood pressure, CRP; C-reactive protein, DBP; diastolic blood pressure, HbA1c; glycated haemoglobin A1, HDL; heavy density lipoprotein.



Supplementary Table 1 | Genetic correlations and partial correlations of twelve trait clusters with mortality. The genetic correlation (rg) between the trait and lifespan was calculated from summary statistics using LD Score regression. The partial correlations (Partial rg), were derived from the genetic correlations using the matrix-inversion method. The lifespan trait is the LifeGen GWAMA for Europeans, both parents combined. CAD; coronary artery disease, T2D; type 2 diabetes, DL/WHR; dyslipidaemia/waist-hip-ratio, BP; blood pressure, Kidney; kidney function, BC; breast cancer, RA; rheumatoid arthritis, AM; age of menarche.

	rg	Partial rg
Smoking	0.68	0.61
CAD	0.66	0.62
T2D	0.48	0.33
DL/WHR	0.41	-0.19
BP	0.39	0.16
Obesity	0.37	0.24
Kidney	0.33	0.34
BC	0.17	0.23
RA	0.17	0.09
AM	-0.15	-0.01
Happiness	-0.24	-0.19
Edu	-0.5	-0.18

Supplementary Table 2 | Results from the discovery step MR for the 28 traits that were significant, prior to removal of trait overlap.

Exposure	# snps	b	se	pval	pleio_p	qvalue	het_p
Omega-6 fatty acids	13	0.0334	0.0135	1.32E-02	0.0203	3.80E-02	5.49E-03
LDL cholesterol	78	0.0543	0.0091	2.80E-09	0.8981	3.73E-08	1.13E-08
Obesity class 1	18	0.0435	0.0066	4.76E-11	0.2723	9.52E-10	4.95E-01
Alzheimer's disease	20	0.0181	0.0064	4.59E-03	0.725	1.53E-02	3.33E-01
HDL cholesterol	85	-0.0448	0.0127	4.07E-04	0.1318	1.55E-03	3.56E-14
Total cholesterol	85	0.0554	0.0096	9.41E-09	0.386	9.06E-08	2.75E-09
Coronary heart disease	39	0.0806	0.0109	1.67E-13	0.926	1.34E-11	6.10E-12
Extreme body mass index	7	0.0257	0.0063	4.08E-05	0.882	1.92E-04	2.92E-01
Myocardial infarction	25	0.0643	0.011	5.80E-09	0.1206	6.63E-08	1.16E-05
Omega-3 fatty acids	6	0.0302	0.0122	1.33E-02	0.5887	3.80E-02	5.28E-01
Years of schooling	69	-0.1774	0.0266	2.69E-11	0.0139	7.18E-10	1.37E-03
DBP	9	0.0144	0.0028	3.94E-07	0.1805	2.87E-06	1.99E-01
Hip circumference	52	0.0976	0.0218	7.86E-06	0.7006	4.49E-05	3.41E-07
Type 2 diabetes	25	0.0175	0.0069	1.15E-02	0.178	3.64E-02	2.20E-01
CRP	48	-0.041	0.0109	1.67E-04	0.9083	7.03E-04	3.31E-15
Obesity class 3	2	0.0237	0.0065	2.58E-04	NA	1.03E-03	1.00E+00
Apolipoprotein B	19	0.0535	0.0093	1.02E-08	0.5418	9.06E-08	3.57E-02
Body mass index	78	0.1226	0.0173	1.26E-12	0.3865	5.03E-11	1.01E-05
Triglycerides	54	0.0326	0.0129	1.18E-02	0.2659	3.64E-02	3.66E-06
Fasting insulin	14	0.1619	0.0501	1.23E-03	0.6666	4.29E-03	8.65E-01
SBP	8	0.0088	0.002	1.12E-05	0.0341	5.98E-05	2.16E-01
Obesity class 2	11	0.0335	0.0059	1.68E-08	0.9266	1.35E-07	3.67E-01
Childhood obesity	10	0.036	0.0109	1.00E-03	0.0475	3.64E-03	2.93E-05
Squamous cell lung cancer	3	0.0494	0.0098	4.86E-07	0.3085	3.24E-06	4.06E-01
Breast Cancer	111	0.0155	0.0039	6.65E-05	0.5674	2.95E-04	3.45E-02
Overweight	14	0.0592	0.0125	2.25E-06	0.3002	1.38E-05	1.45E-01
Cigarettes smoked per day	rs12914385	0.0169	0.0027	6.47E-10	NA	1.03E-08	NA
Ischaemic stroke	rs4984814	0.0058	0.0013	1.39E-05	NA	6.97E-05	NA

Supplementary Table 3 | Number of SNPs which composed the Instrumental Variables before and after pruning

Trait	Initial N SNPs	LD pruned SNPs
Alzheimer's disease	20	18
Apolipoprotein B	21	3
Breast Cancer	134	131
Body mass index SD (kg/m^2)	79	66
Cigarettes smoked per day	1	1
Coronary heart disease	41	28
CRP	53	44
DBP	9	3
Fasting insulin log pmol/L	14	6
HDL cholesterol SD (mg/dL)	89	40
Ischaemic stroke	1	1
LDL cholesterol SD (mg/dL)	80	17
Omega-3 fatty acids SD	6	1
SBP	11	4
Squamous cell lung cancer	4	3
Total cholesterol SD (mg/dL)	88	12
Triglycerides SD (mg/dL)	54	18
Type 2 diabetes	34	29
Years of schooling SD (years)	73	67

Supplementary Note 1 | Cohort and Consortium Acknowledgements

ACPRC was supported by Biotechnology and Biological Sciences Research Council grant BBFO22441/1.
The ARIC study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The study was funded in part by R56 DK104806-01A1 and R21HL123677-01 to NF R01-DK089256 (North), N01-HC-55015, N01-HC-55016, N01-C-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367, R01HL086694, U01HG004402, HHSN268200625226C, UL1RR025005, UL1 RR 025005. Contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.
The Austrian Stroke Prevention Family Study: The research reported in this article was funded by the Austrian Science Fund (FWF) grants number PI904, P20545-P05 and P13180. The Medical University of Graz and the Steiermärkische Krankenanstalten Gesellschaft support the databank of the ASPS-Fam. The authors thank the staff and the participants of the ASPS-Fam for their valuable contributions. The authors thank Birgit Reinhart for her long-term administrative commitment and Ing Johann Semmler for the technical assistance at creating the DNA bank.
Berlin Aging Study II (BASE-II) was supported by the German Federal Ministry of Education and Research (BMBF [grants #16SV5536K, #16SV5537, #16SV5538, and #16SV5837; previously #01UW0808]). Additional contributions (e.g. financial, equipment, logistics, personnel) are made from each of the other participating sites, i.e. the Max Planck Institute for Human Development (MPIB), Max Planck Institute for Molecular Genetics (MPIMG), Charite University Medicine, German Institute for Economic Research (DIW), all located in Berlin, Germany, and University of Lübeck in Lübeck, Germany. Financial support (all to C. Lill) by grants from the Renate Maaß foundation, the German Research Foundation (FOR2488/1, GZ LI 2654/2-1) and the University of Lübeck (medical section, grant number: J21-2016).
Cardiovascular Health Study: This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268200960009C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL085251, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and R01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. B Psaty serves on the DSMB of a clinical trial funded by the manufacturer (Zoll LifeCor) and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson.
CILENTO was supported by PON03PE_00060_7 grant from the Italian Ministry of Universities and Research, Interomics Flagship grant from CNR, Cilento study grant from Assessorato Ricerca Regione Campania, 2011-PDR-13 grant from the Fondazione con il SUD.
The CoLaus study was and is supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 33CSCO-122661, 33CS30-139468, and 33CS30-148401).
The ECGUT study was funded by Estonian Research Council Grant IUT20-60 and PUT1660, EU H2020 grant 692145, and European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.15-0012) GENTRANSMED.

The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002-01254). The ERF study was further supported by ENGAGE consortium and CMSB. High-throughput analysis of the ERF data was supported by a joint grant from Netherlands Organisation for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). Exome sequencing in ERF was supported by the ZonMw grant (project 91111025). We are grateful to all study participants and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection.
GeneSTAR was supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (U01 HL72518, HL087698, HL49762, HL59684, HL58625, HL071025, HL092165, HL099747), National Institutes of Health/National Institute of Nursing Research (NR0224103, NR008153), National Institutes of Health/National Institute of Neurological Disorders and Stroke (NS062059) and by a grant from the National Institutes of Health/National Center for Research Resources (M01-RR000052) to the Johns Hopkins General Clinical Research Center.
GENOA (Genetic Epidemiology Network of Arteriopathy): Support for GENOA was provided by the National Heart, Lung and Blood Institute (HL054464, HL054457, HL054481, HL071917, HL87660, HL119443) of the National Institutes of Health. Genotyping was performed at the Mayo Clinic. We thank Eric Boerwinkle, PhD and Megan L. Grove from the Human Genetics Center and Institute of Molecular Medicine and Division of Epidemiology, University of Texas Health Science Center - Houston, for their help with genotyping. We would also like to thank the families that participated in the GENOA study.
Genotyping of the GS:SFHS samples was carried out by the Edinburgh Clinical Research Facility, University of Edinburgh and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award “STratifying Resilience and Depression Longitudinally” (STRADL) (Reference 104036/Z/14/Z). GS20K received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. The MRC provides core funding to the QTL in Health and Disease research program at the MRC HGU, IGMM, University of Edinburgh.
The Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health (project # Z01-AG000513 and human subjects protocol number 09-AG-N248). The authors would like to thank study participants and the HANDLS medical staff. The authors also would like to thank Dr. Michael A. Nalls for their help in variant calling and genotype quality control. Data analyses for the HANDLS study utilized the high-performance computational resources of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, Maryland, USA (http://hpc.nih.gov).
HRS is supported by the National Institute on Aging (NIA U01AG009740). Genotyping was funded separately by NIA (RC2 AG036495, RC4 AG039029). Our genotyping was conducted by the NIH Center for Inherited Disease Research (CIDR) at Johns Hopkins University. Genotyping quality control and final preparation of the data were performed by the Genetics Coordinating Center at the University of Washington.
The iPSYCH project is funded by the Lundbeck Foundation, the universities and university hospitals of Aarhus and Copenhagen and Statens Staten Serums Institute (R155-2014-1724 & R102-A9118). Y WANG: YW is funded through the FRIPRO Mobility Grant, contract no 251134 as part of EU7 Marie Curie grant no 608695.
We thank the Jackson Heart Study (JHS) participants and staff for their contributions to this work. The JHS is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. Dr. Wilson is supported by U54GM115428 from the National Institute of General Medical Sciences.

For the MICROS study, we thank the primary care practitioners and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. In South Tyrol, the study was supported by the Ministry of Health and Department for Innovation, Universities and Research of the Autonomous Province of Bolzano, South Tyrol, the South Tyrolean Sparkasse Foundation, and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947).
The Nijmegen Biomedical Study is a population-based survey conducted at the Department for Health Evidence and the Department of Laboratory Medicine of the Radboud university medical center. The set-up of NBS was financed by the Radboudumc, the municipality Nijmegen and the community health service Nijmegen. Principal investigators of the Nijmegen Biomedical Study are L.A.L.M. Kiemeney, A.L.M. Verbeek, D.W. Swinkels and B. Franke.
NSHD are very grateful to the members of this birth cohort for their continuing interest and participation in the study. This work was funded by the Medical Research Council [MC_UU_12019/1]. Data used in this publication are available to bona fide researchers upon request to the NSHD Data Sharing Committee via a standard application procedure. Further details can be found at http://www.nshd.mrc.ac.uk/data. doi: 10.5522/NSHD/Q101.
The NTR study was supported by multiple grants from the Netherlands Organization for Scientific Research (NWO: 016-115-035, 463-06-001, 451- 04-034); ZonMW (31160008, 911-09-032); and NWO 480-15-001/674: Netherlands Twin Registry Repository: researching the interplay between genome and environment; The Amsterdam Public Health Institute (APH) and Neuroscience Campus Amsterdam (NCA); Biomolecular Resources Research Infrastructure (BBMRI–NL, 184.021.007), European Research Council (ERC-230374); Genotyping was made possible by grants from NWO/SPI 56-464-14192, Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health, Rutgers University Cell and DNA Repository (NIMH U24 MH068457-06), the Avera Institute, Sioux Falls (USA) and the National Institutes of Health (NIH R01 HD042157-01A1, MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995).
OGP was suppoted by a a grant from the Italian Ministry of Education, University and Research (MIUR) n°: 5571/DSPAR/2002.
ORCADES was supported by the Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710), the Royal Society, the MRC Human Genetics Unit, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). DNA extractions were performed at the Wellcome Trust Clinical Research Facility in Edinburgh. We would like to acknowledge the invaluable contributions of the research nurses in Orkney, the administrative team in Edinburgh and the people of Orkney.
The PROSPER study was supported by an investigator initiated grant obtained from Bristol-Myers Squibb. Prof. Dr. J. W. Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (grant 2001 D 032). Support for genotyping was provided by the seventh framework program of the European commission (grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging grant 050-060-810).
The Australian Research Council (FT110100548) and Australian National Health and Medical Research Council (APP1103623). NHMRC and NIH funding for phenotype collection and genotyping.
The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, PhD, and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, PhD, for the creation and analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam,

Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists.
The Viking Health Study – Shetland (VIKING) was supported by the MRC Human Genetics Unit quinquennial programme grant "QTL in Health and Disease". DNA extractions and genotyping were performed at the Edinburgh Clinical Research Facility, University of Edinburgh. We would like to acknowledge the invaluable contributions of the research nurses in Shetland, the administrative team in Edinburgh and the people of Shetland.
The Vitality 90+ study has been financially supported by the Academy of Finland (grants 286284 (T.L), 132704 (M.H.), and 250602 (Coctel to M.J.); the Finnish Foundation of Cardiovascular Research (T.L.); the Tampere Tuberculosis Foundation (T.L., M.H.); the Emil Aaltonen Foundation (T.L); the Finnish Cultural Foundation, Pirkanmaa Regional fund (N.M); and the Yrjö Jahnsson Foundation (T.L., M.H.) This work was also supported by grants from the Competitive Research Fund of Pirkanmaa Hospital District (9M017, 9N013 to M.H, 9P002 to M.J. and X51001 for T.L.).
The WGHS is supported by the National Heart, Lung, and Blood Institute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and UM1CA182913) with funding for genotyping provided by Amgen.
BCAC is funded by Cancer Research UK [C1287/A16563, C1287/A10118], the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and by the European Community´s Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) (COGS). Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

Supplementary Data 2 | Summary Statistics for each cohort.

					Age			
Ancestry	Cohort	Parent	Dead	Count	max	mean	min	SD
African	ARIC_AA	Father	FALSE	433	96	76.6	59	7.3
African	ARIC_AA	Father	TRUE	1285	99	70	41	11.4
African	ARIC_AA	Mother	FALSE	812	99	75	55	7.6
African	ARIC_AA	Mother	TRUE	1031	99	67.4	41	12.1
African	CHS_AA	Father	FALSE	8	105	94.2	87	6.4
African	CHS_AA	Father	TRUE	601	103	70.8	41	14.1
African	CHS_AA	Mother	FALSE	35	100	90	84	4.3
African	CHS_AA	Mother	TRUE	577	104	71.8	41	14.9
African	GeneSTAR_AA	Father	FALSE	245	93	66.7	45	9.4
African	GeneSTAR_AA	Father	TRUE	349	98	64.9	41	11.6
African	GeneSTAR_AA	Mother	FALSE	347	95	66.6	41	11
African	GeneSTAR_AA	Mother	TRUE	265	94	67.1	41	12.6
African	GENOA_AA	Father	FALSE	78	100	80	57	9.4
African	GENOA_AA	Father	TRUE	331	102	71.8	41	12.5
African	GENOA_AA	Mother	FALSE	146	96	78.4	54	9.7
African	GENOA_AA	Mother	TRUE	282	106	73.6	43	12.2
African	HANDLS	Father	FALSE	450	95	65.8	41	12
African	HANDLS	Father	TRUE	263	94	68.5	47	10.2
African	HANDLS	Mother	FALSE	367	97	65.7	41	12.5
African	HANDLS	Mother	TRUE	467	99	68.7	46	10.7
African	HRS_AA	Father	FALSE	224	104	79.2	55	7.5
African	HRS_AA	Father	TRUE	1691	106	71	41	12.5
African	HRS_AA	Mother	FALSE	564	103	78.6	53	7.9
African	HRS_AA	Mother	TRUE	1503	113	72.1	41	13.7
African	JHS	Father	FALSE	609	99	69.7	41	11.4
African	JHS	Father	TRUE	1649	109	70.3	41	12.7

African	JHS	Mother	FALSE	1212	105	71.1	42	11.2
African	JHS	Mother	TRUE	1228	110	71.4	41	13.6
African	ukbbafric	Father	FALSE	133	97	78	60	7.7
African	ukbbafric	Father	TRUE	378	115	73	41	12.9
African	ukbbafric	Mother	FALSE	277	106	75.2	60	8.4
African	ukbbafric	Mother	TRUE	254	109	72.9	41	13.8
African	ukbbcarib	Father	FALSE	255	99	77	60	6.7
African	ukbbcarib	Father	TRUE	377	103	71.6	41	12
African	ukbbcarib	Mother	FALSE	425	94	74.8	60	6.7
African	ukbbcarib	Mother	TRUE	282	103	71.1	42	11.9
European	ACPRC	Father	FALSE	52	96	84	74	5.2
European	ACPRC	Father	TRUE	1369	98	70.2	41	11.9
European	ACPRC	Mother	FALSE	202	96	84.1	64	5.8
European	ACPRC	Mother	TRUE	1250	101	75	41	11.6
European	ARIC_EA	Father	FALSE	1793	99	78.3	62	6.4
European	ARIC_EA	Father	TRUE	6549	99	69.5	41	11.7
European	ARIC_EA	Mother	FALSE	4206	99	77.6	58	6.9
European	ARIC_EA	Mother	TRUE	4342	99	71.7	41	12
European	ASPSFam	Father	TRUE	144	95	72.8	41	11.9
European	ASPSFam	Mother	FALSE	9	96	84.8	68	10.5
European	ASPSFam	Mother	TRUE	142	99	78.8	42	13.4
European	BASEII	Father	FALSE	31	109	92.3	83	6.1
European	BASEII	Father	TRUE	1132	100	73.5	41	12.4
European	BASEII	Mother	FALSE	128	105	89.6	82	4.4
European	BASEII	Mother	TRUE	1320	104	78.8	41	12.6
European	CHS_EA	Father	FALSE	19	100	92.7	86	3.9
European	CHS_EA	Father	TRUE	2799	101	72.7	41	12.8
European	CHS_EA	Mother	FALSE	114	106	92.6	83	4
European	CHS_EA	Mother	TRUE	2677	105	77	41	13.2
European	CILENTO	Father	FALSE	86	98	75.1	45	14.9

European	CILENTO	Father	TRUE	539	98	75.9	42	11.6
European	CILENTO	Mother	FALSE	144	100	76.4	43	14.7
European	CILENTO	Mother	TRUE	478	101	79.4	42	10.9
European	CoLaus	Father	FALSE	1873	101	74.7	53	7.9
European	CoLaus	Father	TRUE	3178	103	71.6	41	12.3
European	CoLaus	Mother	FALSE	2890	101	74.7	49	8.8
European	CoLaus	Mother	TRUE	2163	103	75.3	41	13
European	EGCUT_core	Father	FALSE	2399	98	59.1	41	9.6
European	EGCUT_core	Father	TRUE	1293	97	63.5	41	12.2
European	EGCUT_core	Mother	FALSE	3235	103	59	41	10.4
European	EGCUT_core	Mother	TRUE	792	99	69.3	41	13.3
European	EGCUT_omni	Father	FALSE	1656	102	61.6	41	11.9
European	EGCUT_omni	Father	TRUE	3374	106	67.7	41	13.2
European	EGCUT_omni	Mother	FALSE	2605	105	64	41	12.9
European	EGCUT_omni	Mother	TRUE	2895	107	73.9	41	12.8
European	ERF	Father	FALSE	466	117	71.3	54	9.1
European	ERF	Father	TRUE	490	93	70	41	11
European	ERF	Mother	FALSE	597	116	70.7	52	9.8
European	ERF	Mother	TRUE	378	98	75.1	41	12.2
European	GeneSTAR_EA	Father	FALSE	408	100	68.9	45	9.7
European	GeneSTAR_EA	Father	TRUE	620	94	67.1	41	12.3
European	GeneSTAR_EA	Mother	FALSE	600	97	70.8	44	11.3
European	GeneSTAR_EA	Mother	TRUE	445	99	73.3	42	11.7
European	GENOA_EA	Father	FALSE	120	93	76.2	59	7.8
European	GENOA_EA	Father	TRUE	367	95	70.5	42	11.8
European	GENOA_EA	Mother	FALSE	240	97	77.2	52	8.7
European	GENOA_EA	Mother	TRUE	253	99	74.8	43	11.9
European	GS20K	Father	FALSE	5538	106	64.5	41	11.7
European	GS20K	Father	TRUE	6257	109	70	41	11.9
European	GS20K	Mother	FALSE	7249	114	66.1	41	13

European	GS20K	Mother	TRUE	4822	105	73.7	41	12.4
European	HRS_EA	Father	FALSE	1034	104	80.4	53	7
European	HRS_EA	Father	TRUE	8406	104	72.4	41	12.4
European	HRS_EA	Mother	FALSE	2137	103	81.3	52	7.6
European	HRS_EA	Mother	TRUE	7380	108	77.2	41	12.6
European	IPSYCH	Father	FALSE	58242	70	52.4	41	6.9
European	IPSYCH	Father	TRUE	2982	78	53.3	41	8.3
European	IPSYCH	Mother	FALSE	56733	66	50.4	41	5.9
European	IPSYCH	Mother	TRUE	1308	65	49.9	41	6
European	MICROS	Father	FALSE	231	90	66	45	9.9
European	MICROS	Father	TRUE	551	98	71.6	41	11.6
European	MICROS	Mother	FALSE	430	92	65.9	41	10.6
European	MICROS	Mother	TRUE	389	99	75.2	41	12.3
European	NSHD	Father	FALSE	453	95	80.9	70	4.3
European	NSHD	Father	TRUE	1746	100	70.6	42	10.6
European	NSHD	Mother	FALSE	993	95	79.9	69	4.6
European	NSHD	Mother	TRUE	1232	95	72	41	10.6
European	NBS	Father	FALSE	1231	113	65.1	44	10.9
European	NBS	Father	TRUE	3121	101	72.5	41	11.8
European	NBS	Mother	FALSE	1735	117	68.1	41	12.7
European	NBS	Mother	TRUE	2608	103	76.5	41	12
European	NTR	Father	FALSE	2799	109	65.9	41	10.5
European	NTR	Father	TRUE	1573	101	72.1	41	11.2
European	NTR	Mother	FALSE	3473	108	66.9	41	11.9
European	NTR	Mother	TRUE	1047	103	74.6	41	11.9
European	OGP	Father	FALSE	251	100	69	41	13.3
European	OGP	Father	TRUE	385	104	75.2	41	13
European	OGP	Mother	FALSE	359	100	68.9	41	13.6
European	OGP	Mother	TRUE	271	100	78	41	13.3
European	ORCADES	Father	FALSE	166	95	71.8	52	8.8

European	ORCADES	Father	TRUE	322	98	72	41	12
European	ORCADES	Mother	FALSE	249	99	72.1	49	10.3
European	ORCADES	Mother	TRUE	259	100	75	41	12.3
European	PROSPER	Father	FALSE	2	93	91.5	90	2.1
European	PROSPER	Father	TRUE	4913	108	72.6	41	11.9
European	PROSPER	Mother	FALSE	32	98	92.7	90	2
European	PROSPER	Mother	TRUE	4885	104	75.6	41	12.5
European	QIMRBerghofer	Father	FALSE	2068	96	68.6	42	9.6
European	QIMRBerghofer	Father	TRUE	2299	99	69.9	41	11.6
European	QIMRBerghofer	Mother	FALSE	2844	99	68.9	41	10.6
European	QIMRBerghofer	Mother	TRUE	1563	99	72.9	41	12.4
European	RS1	Father	FALSE	140	99	86.3	74	5
European	RS1	Father	TRUE	5202	103	73.3	41	11.9
European	RS1	Mother	FALSE	673	105	85.7	72	5.1
European	RS1	Mother	TRUE	4730	103	76	41	12.3
European	RS2	Father	FALSE	87	101	85.8	77	4.5
European	RS2	Father	TRUE	1572	102	72.9	41	11.8
European	RS2	Mother	FALSE	357	101	85.6	76	4.7
European	RS2	Mother	TRUE	1357	103	77.2	41	11.7
European	ukbbbriti	Father	FALSE	3608	101	77.6	60	7.7
European	ukbbbriti	Father	TRUE	11925	106	71.2	41	11.6
European	ukbbbriti	Mother	FALSE	6487	103	78.3	60	8.2
European	ukbbbriti	Mother	TRUE	9593	103	74.5	41	12
European	ukbbg_bri	Father	FALSE	26078	102	77.9	60	7.3
European	ukbbg_bri	Father	TRUE	86034	105	71.4	41	11.6
European	ukbbg_bri	Mother	FALSE	45318	105	78.5	60	8.1
European	ukbbg_bri	Mother	TRUE	69823	107	75	41	12
European	ukbbirish	Father	FALSE	627	100	77.6	61	7.1
European	ukbbirish	Father	TRUE	2895	100	70.9	41	11.7
European	ukbbirish	Mother	FALSE	1255	101	78.5	60	7.9

European	ukbbirish	Mother	TRUE	2364	101	73.9	41	12.2
European	VIKING	Father	FALSE	251	96	69.2	43	10.1
European	VIKING	Father	TRUE	359	99	71.5	41	13
European	VIKING	Mother	FALSE	344	99	70	41	11.9
European	VIKING	Mother	TRUE	272	103	76	41	13.2
European	Vitality90	Father	TRUE	215	98	68.7	41	13.1
European	Vitality90	Mother	TRUE	229	102	74.8	43	13.1
European	WGHS	Father	FALSE	1902	102	86	72	4.7
European	WGHS	Father	TRUE	15406	105	74	41	12.3
European	WGHS	Mother	FALSE	5216	104	85.7	70	5.2
European	WGHS	Mother	TRUE	12877	105	78.2	41	12.2

Supplementary Data 3 | Lookup of previously reported longevity associations in present lifespan study

							Previously Reported Associations				Validation in LifeGen						Effect Comparison			
rsid	Gene Region	Source	Chr	Position	a1	a0	OR a1	SE	P1	Source Trait	Freq a1	N	HR a1	SE	Years	P2	Reported OR	SE	Extrapolated OR	SE
rs1333049	CDKN2A/B	Emanuele et al., 2010	9	22125503	C	G	0.6400	0.1250	<0.01*	>100	0.4798	567124	1.0249	0.0027	-0.2460	6.92E-06	0.6400	0.1250	0.8913	0.0253
rs4977756		Fortney et al., 2015	9	22068652	A	G	0.7300	0.0650	7.97E-06	>90 & 95-119	0.5979	555956	1.0159	0.0028	-0.1580	5.42E-03	0.7300	0.0650	0.9287	0.0262
rs3184504	SH2B3	Fortney et al., 2015	12	111884608	T	C	0.7900	0.0700	7.88E-07	>90 & 95-119	0.4709	569984	1.0235	0.0027	-0.2320	2.23E-05	0.7900	0.0700	0.8971	0.0253
rs3800231		Flachsbart et al., 2009	6	108998266	G	A	0.8264	0.0675	0.025*	95-110	0.7059	569997	1.0214	0.0031	-0.2120	5.13E-04	0.8264	0.0675	0.9056	0.0290
rs2802292	FOXO3	Willcox et al., 2008	6	108908518	T	G	0.5236	0.1114	0.0003*	>95	0.6129	569993	1.0196	0.0028	-0.1940	5.13E-04	0.5236	0.1114	0.9132	0.0262
rs10457180		Broer et al., 2015	6	108965039	A	G	0.8700	0.0300	8.56E-05	>90	0.6959	569993	1.0206	0.0031	-0.2040	8.29E-04	0.8700	0.0300	0.9090	0.0290
rs514659	ABO	Fortney et al., 2015	9	136142203	C	A	0.8929	0.0298	2.51E-07	>90 & 95-119	0.3313	567380	1.0072	0.0029	-0.0720	0.2217	0.8929	0.0298	0.9669	0.0271
rs2149954	5q33.3/EBF1	Deelen et al., 2014	5	157820602	C	T	0.9091	0.0172	1.74E-08	>90	0.6313	567926	1.0050	0.0028	-0.0500	0.3789	0.9091	0.0172	0.9769	0.0262
rs10491334	CAMK4	Malovini et al., 2011	5	110772404	T	C	0.5500	0.0650	2.88E-05	-	0.1933	567928	1.0058	0.0034	-0.0580	0.3891	0.5500	0.0650	0.9732	0.0318
rs9825185	C3orf21	Newman et al., 2010	3	196415923	A	C	0.6900	0.0658	2.5E-06	>90	0.8653	569997	1.0070	0.0041	-0.0700	0.3937	0.6900	0.0658	0.9678	0.0384
rs954551	GRIK2	Newman et al., 2010	6	102779335	G	C	0.7692	0.0507	5.3E-06	>90	0.7366	569981	0.9960	0.0032	0.0400	0.5263	0.7692	0.0507	1.0189	0.0299
rs1416280		Broer et al., 2015	6	102886643	G	C	0.8065	0.0355	5.09E-08	>90	0.7387	569988	0.9960	0.0033	0.0400	0.5398	0.8065	0.0355	1.0189	0.0309
rs2069837	IL6	Zeng et al., 2016	7	22768027	G	A	0.6098	0.0649	1.8E-09	>100	0.0814	569995	1.0064	0.0054	-0.0640	0.5509	0.6098	0.0649	0.9705	0.0505
rs4611001	RGS7	Broer et al., 2015	1	240741328	G	A	0.5587	0.0753	1.84E−06	>90	0.9674	565839	0.9918	0.0086	0.0820	0.6346	0.5587	0.0753	1.0391	0.0805
rs4443878		Newman et al., 2010	1	238971041	T	C	0.4100	0.1219	1.3E−06	>90	0.9683	567911	0.9922	0.0086	0.0780	0.6512	0.4100	0.1219	1.0372	0.0805
rs9841144	CADM2	Broer et al., 2015	3	85482049	A	T	0.8100	0.0350	9.66E−07	>90	0.7702	567926	1.0024	0.0033	-0.0240	0.7129	0.8100	0.0350	0.9888	0.0309
rs9664222	MINPP1	Newman et al., 2010	10	89338633	A	C	0.8200	0.0362	6.77E-07	>90	0.7762	569991	0.9988	0.0033	0.0120	0.8541	0.8200	0.0362	1.0056	0.0309
rs2440012	ANKRD20A9P	Zeng et al., 2016	13	19440123	G	C	0.6024	0.0722	3.73E-08	>100	0.1796	455092	1.0010	0.0043	-0.0100	0.9077	0.6024	0.0722	0.9953	0.0402

Supplementary Data 4 | Previous association reports for the four genome-wide significant loci, acquired through PhenoScanner.

Query rsid	Locus	Proxy rsid	Proxy Position	r2	Trait	Study	PMID	Year of Publication	P
rs5573049-C	LPA	rs55730499	chr6:161005610	1	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	5.39E-39
rs5573049-C	LPA	rs55730499	chr6:161005610	1	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	2.37E-26
rs5573049-C	LPA	rs55730499	chr6:161005610	1	Lipoprotein A Lpa	Wood	23696881	2013	2.34E-26
rs5573049-C	LPA	rs74617384	chr6:160997118	0.986	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	1.72E-38
rs5573049-C	LPA	rs74617384	chr6:160997118	0.986	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	1.25E-26
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Coronary artery disease	CARDIoGRAM	21378990	2011	3.08E-13
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	5.73E-39
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	9.23E-27
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Aortic valve calcification	CHARGE	23388002	2013	9.01E-10
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	log(eGFR creatinine)	CKD-Gen	26831199	2016	2.30E-05
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	log(eGFR creatinine in non diabetics)	CKD-Gen	26831199	2016	9.70E-06
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL	GLGC	20686565	2010	1.36E-15
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL	GLGC	24097068	2013	1.94E-15
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Total cholesterol	GLGC	20686565	2010	2.66E-16
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Total cholesterol	GLGC	24097068	2013	7.24E-17
rs5573049-C	LPA	rs118039278	chr6:160985526	0.972	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	4.38E-37
rs5573049-C	LPA	rs118039278	chr6:160985526	0.972	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	3.69E-25
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Aortic valve calcification	CHARGE	23388002	2013	3.00E-11
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Cholesterol LDL	Chasman DI	22331829	2012	5.00E-15
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Response to statin therapy LDL C	Chasman DI	22331829	2012	5.00E-15
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	ted phospholipase A2 activity change in respon	Chu AY	23118302	2012	2.00E-16
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Cholesterol LDL	Deshmukh HA	22368281	2012	1.00E-09
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Response to statin therapy	Deshmukh HA	22368281	2012	1.00E-09
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Coronary artery disease or ischemic stroke	Dichgans M	24262325	2013	2.00E-12
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Coronary artery disease or large artery stroke	Dichgans M	24262325	2013	9.00E-14
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Response to statins LDL cholesterol change	Postmus I	25350695	2014	7.00E-44
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	lipoprotein A I Supplementary Concept	Qi Q	21900290	2011	5.00E-39
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Lp a levels	Qi Q	21900290	2011	5.00E-39
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL cholesterol	Asselbergs	23063622	2012	2.23E-24
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Total cholesterol	Asselbergs	23063622	2012	3.81E-20
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Aortic valve and mitral annular calcium	CHARGE	23388002	2013	3.17E-138
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Aortic valve calcium	CHARGE	23388002	2013	9.00E-10
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	erol response to statins absolute change in LDL	Chasman DI	22331829	2012	3.50E-09
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	erol response to statins fractional change in LDL	Chasman DI	22331829	2012	5.00E-15
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	to statins residuals of the measure of absolute	Chasman DI	22331829	2012	7.00E-11
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	to statins residuals of the measure of fractional	Chasman DI	22331829	2012	1.50E-17
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	d change in lipoprotein associated phospholipas	Chu AY	23118302	2012	1.60E-16
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Serum creatinine	CKD-Gen	20383146	2010	8.70E-04
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Coronary artery disease CAD	Clarke	20032323	2009	3.00E-15
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Plasma lipoprotein A Lpa	Clarke	20032323	2009	3.60E-166

rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL cholesterol response to statins	Deshmukh HA	22368281	2012	1.20E-09
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	erol response to statins first post treatment LDL	Deshmukh HA	22368281	2012	3.01E-08
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL cholesterol	GLGC	20686565	2010	3.55E-21
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Total cholesterol	GLGC	20686565	2010	2.67E-23
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	APOB apolipoprotein B	Hopewell	23100282	2012	1.50E-11
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	oprotein B response after 40mg daily simvastat	Hopewell	23100282	2012	6.50E-31
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL cholesterol	Hopewell	23100282	2012	2.20E-04
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	esterol response after 40mg daily simvastatin tr	Hopewell	23100282	2012	8.10E-28
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL cholesterol	Kathiresan S	19060906	2008	8.54E-05
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL cholesterol	Musunuru	22629316	2012	2.81E-12
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL cholesterol female	Musunuru	22629316	2012	1.95E-09
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL cholesterol male	Musunuru	22629316	2012	7.61E-05
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Plasma lipoprotein A Lpa in Type 2 diabetes	Qi Q	21900290	2011	4.60E-39
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Coronary artery disease CAD	Visscher	21966275	2011	1.20E-20
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Lipoprotein A Lpa	Wood	23696881	2013	5.06E-25
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	APOB apolipoprotein B	Zabaneh	21592478	2011	2.26E-04
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	LDL cholesterol	Zabaneh	21592478	2011	1.95E-04
rs5573049-C	LPA	rs10455872	chr6:161010118	0.972	Plasma lipoprotein A Lpa	Zabaneh	21592478	2011	2.94E-306
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	Coronary artery disease	CARDIoGRAM	21378990	2011	5.04E-06
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	2.88E-34
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	2.42E-24
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	Aortic valve calcification	CHARGE	23388002	2013	3.26E-07
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	LDL	GLGC	20686565	2010	2.82E-12
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	LDL	GLGC	24097068	2013	5.23E-12
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	Total cholesterol	GLGC	20686565	2010	3.56E-11
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	Total cholesterol	GLGC	24097068	2013	1.10E-11
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	Aortic valve and mitral annular calcium	CHARGE	23388002	2013	1.23E-97
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	Aortic valve calcium	CHARGE	23388002	2013	3.26E-07
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	LDL cholesterol	GLGC	20686565	2010	2.82E-12
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	Total cholesterol	GLGC	20686565	2010	3.56E-11
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	LDL cholesterol	Kathiresan S	19060906	2008	3.74E-04
rs5573049-C	LPA	rs2315065	chr6:161108144	0.674	Plasma lipoprotein A Lpa in Type 2 diabetes	Qi Q	21900290	2011	1.15E-23
rs5573049-C	LPA	rs4252185	chr6:161123451	0.669	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	1.64E-32
rs5573049-C	LPA	rs4252185	chr6:161123451	0.669	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	9.83E-24
rs8042849-C	CHRNA	rs8042849	chr15:78817929	1	Schizophrenia	PGC	25056061	2014	4.54E-06
rs8042849-C	CHRNA	rs9788721	chr15:78802869	0.979	Cigarettes per day	TAG	20418890	2010	4.14E-31
rs8042849-C	CHRNA	rs9788721	chr15:78802869	0.979	Local histogram emphysema pattern	Castaldi PJ	25006744	2014	1.00E-12
rs8042849-C	CHRNA	rs9788721	chr15:78802869	0.979	Local histogram emphysema pattern	Castaldi PJ	25006744	2014	2.00E-13
rs8042849-C	CHRNA	rs9788721	chr15:78802869	0.979	Lung cancer	Hung RJ	18385738	2008	6.31E-09
rs8042849-C	CHRNA	rs9788721	chr15:78802869	0.979	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	2.97E-64
rs8042849-C	CHRNA	rs9788721	chr15:78802869	0.979	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	5.00E-68
rs8042849-C	CHRNA	rs9788721	chr15:78802869	0.979	Airflow obstruction all	Wilk JB	22837378	2012	1.04E-06
rs8042849-C	CHRNA	rs9788721	chr15:78802869	0.979	Airflow obstruction ever smokers	Wilk JB	22837378	2012	9.76E-09
rs8042849-C	CHRNA	rs10519203	chr15:78814046	0.951	Schizophrenia	PGC	25056061	2014	5.89E-06
rs8042849-C	CHRNA	rs10519203	chr15:78814046	0.951	Cigarettes per day	TAG	20418890	2010	4.89E-31
rs8042849-C	CHRNA	rs10519203	chr15:78814046	0.951	moking status alcohol consumption or body ma	Baumert J	25551457	2014	6.00E-08

rs8042849-C	CHRNA	rs10519203	chr15:78814046	0.951	Lung cancer	Hung RJ	18385738	2008	6.31E-09
rs8042849-C	CHRNA	rs10519203	chr15:78814046	0.951	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	3.12E-63
rs8042849-C	CHRNA	rs10519203	chr15:78814046	0.951	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	3.10E-67
rs8042849-C	CHRNA	rs10519203	chr15:78814046	0.951	Airflow obstruction all	Wilk JB	22837378	2012	7.16E-07
rs8042849-C	CHRNA	rs10519203	chr15:78814046	0.951	Airflow obstruction ever smokers	Wilk JB	22837378	2012	5.67E-09
rs8042849-C	CHRNA	rs8031948	chr15:78816057	0.935	Schizophrenia	PGC	25056061	2014	2.42E-06
rs8042849-C	CHRNA	rs8031948	chr15:78816057	0.935	Cigarettes per day	TAG	20418890	2010	3.15E-31
rs8042849-C	CHRNA	rs8031948	chr15:78816057	0.935	Airflow obstruction	Wilk JB	22837378	2012	3.00E-09
rs8042849-C	CHRNA	rs8031948	chr15:78816057	0.935	Lung cancer	Hung RJ	18385738	2008	1.00E-10
rs8042849-C	CHRNA	rs8031948	chr15:78816057	0.935	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	1.62E-64
rs8042849-C	CHRNA	rs8031948	chr15:78816057	0.935	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	4.60E-68
rs8042849-C	CHRNA	rs8031948	chr15:78816057	0.935	Airflow obstruction all	Wilk JB	22837378	2012	4.76E-07
rs8042849-C	CHRNA	rs8031948	chr15:78816057	0.935	Airflow obstruction ever smokers	Wilk JB	22837378	2012	2.78E-09
rs8042849-C	CHRNA	rs931794	chr15:78826180	0.926	Cigarettes per day	TAG	20418890	2010	1.64E-31
rs8042849-C	CHRNA	rs931794	chr15:78826180	0.926	Lung cancer	Hung RJ	18385738	2008	1.26E-08
rs8042849-C	CHRNA	rs931794	chr15:78826180	0.926	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	7.75E-66
rs8042849-C	CHRNA	rs931794	chr15:78826180	0.926	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	7.30E-69
rs8042849-C	CHRNA	rs931794	chr15:78826180	0.926	Airflow obstruction all	Wilk JB	22837378	2012	6.18E-07
rs8042849-C	CHRNA	rs931794	chr15:78826180	0.926	Airflow obstruction ever smokers	Wilk JB	22837378	2012	4.69E-09
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Schizophrenia	PGC	25056061	2014	2.42E-06
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Cigarettes per day	TAG	20418890	2010	1.68E-31
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Amos CI	18385676	2008	3.00E-18
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung Neoplasms	Amos CI	18385676	2008	3.00E-18
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Broderick P	19654303	2009	3.00E-26
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung Neoplasms	Broderick P	19654303	2009	3.00E-26
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Hung RJ	18385738	2008	5.00E-20
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung Neoplasms	Hung RJ	18385738	2008	5.00E-20
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Liu P	18780872	2008	1.00E-08
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung Neoplasms	Liu P	18780872	2008	1.00E-08
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Chronic obstructive pulmonary disease	Pillai SG	19300482	2009	1.00E-10
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Pulmonary Disease Chronic Obstructive	Pillai SG	19300482	2009	1.00E-10
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Amos CI	18385676	2008	3.15E-18
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	ng cancer in current smokers number of cigday	Amos CI	18385676	2008	9.22E-10
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer in smokers pack years 35	Amos CI	18385676	2008	3.47E-06
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer in smokers pack years 35	Amos CI	18385676	2008	6.71E-09
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer in smokers years smoked 35	Amos CI	18385676	2008	4.21E-06
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer in smokers years smoked 35	Amos CI	18385676	2008	4.30E-10
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	oin level the proportion of F cells in sickle cell di	Bhatnagar P	21326311	2011	3.68E-06
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Chronic obstructive pulmonary disease COPD	Brehm	21921092	2011	1.06E-07
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Broderick P	19654303	2009	3.24E-26
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Nicotine dependence smoking cigarettes per da	Caporaso N	19247474	2009	2.00E-29
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Chronic obstructive pulmonary disease COPD	Cho MH	20173748	2010	8.32E-08
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer squamous cell carcinoma	Dong J	23341777	2013	2.00E-10
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	cpression of IREB2 probe 3603377 in peripheral	Heinzen	19222302	2008	2.69E-07
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Hung RJ	18385738	2008	7.94E-10
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer adenocarcinoma	Hung RJ	18385738	2008	2.00E-10

rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer in current smokers	Hung RJ	18385738	2008	3.00E-10
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer in current smokers females	Hung RJ	18385738	2008	2.00E-11
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer in former smokers	Hung RJ	18385738	2008	4.00E-07
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer in smokers pack years 20 39	Hung RJ	18385738	2008	3.00E-08
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer in smokers pack years 40	Hung RJ	18385738	2008	2.00E-06
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer males	Hung RJ	18385738	2008	1.00E-10
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer squamous cell carcinoma	Hung RJ	18385738	2008	6.00E-06
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer with age 50	Hung RJ	18385738	2008	4.00E-17
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Landi MT	19836008	2009	2.18E-46
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer adenocarcinoma	Landi MT	19836008	2009	1.46E-15
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer small cell carcinoma	Landi MT	19836008	2009	4.49E-07
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer squamous cell carcinoma	Landi MT	19836008	2009	3.37E-09
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	1.04E-63
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Liu P	18780872	2008	9.90E-09
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	McKay JD	18978790	2008	4.00E-15
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	tercellular adhesion molecule 1 ICAM 1 in curre	Pare G	21533024	2011	3.50E-08
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Chronic obstructive pulmonary disease COPD	Pillai SG	19300482	2009	1.86E-12
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Soler Artigas M	21946350	2011	2.19E-46
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	d expiratory volume in 1 second FEV1 to forced	Soler Artigas M	21946350	2011	9.65E-06
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Nicotine dependence smoking cigarettes per da	Soler Artigas M	21946350	2011	1.59E-17
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	6.80E-68
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Nicotine dependence smoking quantity	Thorgeirsson TE	18385739	2008	1.00E-15
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Timofeeva MN	22899653	2012	9.50E-59
rs8042849-C	CHRNA	rs8034191	chr15:78806023	0.919	Lung cancer	Wang Y	18978787	2008	3.94E-19
rs8042849-C	CHRNA	rs72738786	chr15:78828086	0.902	Schizophrenia	PGC	25056061	2014	1.42E-06
rs8042849-C	CHRNA	rs55853698	chr15:78857939	0.887	Schizophrenia	PGC	25056061	2014	8.98E-07
rs8042849-C	CHRNA	rs55853698	chr15:78857939	0.887	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	1.31E-16
rs8042849-C	CHRNA	rs72740955	chr15:78849779	0.883	Schizophrenia	PGC	25056061	2014	4.14E-07
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Schizophrenia	PGC	25056061	2014	4.57E-07
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Cigarettes per day	TAG	20418890	2010	1.20E-32
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Smoking behavior	David SP	22832964	2012	2.00E-08
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Pulmonary function	Soler Artigas M	21946350	2011	7.00E-07
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Respiratory Function Tests	Soler Artigas M	21946350	2011	7.00E-07
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Nicotine dependence smoking	David SP	22832964	2012	1.84E-08
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Lung cancer	Hung RJ	18385738	2008	7.94E-11
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	6.62E-65
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Chronic obstructive pulmonary disease COPD	Pillai SG	19300482	2009	3.91E-06
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	function forced expiratory volume in 1 second	Soler Artigas M	21946350	2011	2.40E-06
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Nicotine dependence smoking cigarettes per da	Soler Artigas M	21946350	2011	6.34E-18
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	1.60E-67
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Airflow obstruction all	Wilk JB	22837378	2012	3.51E-07
rs8042849-C	CHRNA	rs2036527	chr15:78851615	0.883	Airflow obstruction ever smokers	Wilk JB	22837378	2012	1.72E-08
rs8042849-C	CHRNA	rs55781567	chr15:78857986	0.883	Schizophrenia	PGC	25056061	2014	8.93E-07
rs8042849-C	CHRNA	rs58365910	chr15:78849034	0.879	Schizophrenia	PGC	25056061	2014	5.67E-07
rs8042849-C	CHRNA	rs11852372	chr15:78801394	0.872	Schizophrenia	PGC	25056061	2014	2.94E-06
rs8042849-C	CHRNA	rs11852372	chr15:78801394	0.872	Local histogram emphysema pattern	Castaldi PJ	25006744	2014	2.00E-10

rs8042849-C	CHRNA	rs11852372	chr15:78801394	0.872	Local histogram emphysema pattern	Castaldi PJ	25006744	2014	1.00E-07
rs8042849-C	CHRNA	rs72740964	chr15:78868636	0.837	Schizophrenia	PGC	25056061	2014	6.53E-07
rs8042849-C	CHRNA	rs11633958	chr15:78862064	0.833	Schizophrenia	PGC	25056061	2014	5.61E-07
rs8042849-C	CHRNA	rs7172118	chr15:78862453	0.829	Schizophrenia	PGC	25056061	2014	5.82E-07
rs8042849-C	CHRNA	rs17486195	chr15:78865197	0.829	Schizophrenia	PGC	25056061	2014	6.58E-07
rs8042849-C	CHRNA	rs140330585	chr15:78866445	0.829	Schizophrenia	PGC	25056061	2014	6.79E-07
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Schizophrenia	PGC	25056061	2014	6.48E-06
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Cigarettes per day	TAG	20418890	2010	5.91E-33
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Former smoker	TAG	20418890	2010	7.68E-06
rs8042849-C	CHRNA	rs7180002	chr15:78873993	0.829	BMI in males greater than 50 years of age	GIANT	26426971	2015	1.00E-05
rs8042849-C	CHRNA	rs7180002	chr15:78873993	0.829	Schizophrenia	PGC	25056061	2014	6.15E-07
rs8042849-C	CHRNA	rs7180002	chr15:78873993	0.829	Cigarettes per day	TAG	20418890	2010	4.11E-33
rs8042849-C	CHRNA	rs7180002	chr15:78873993	0.829	Former smoker	TAG	20418890	2010	6.97E-06
rs8042849-C	CHRNA	rs951266	chr15:78878541	0.829	Schizophrenia	PGC	25056061	2014	6.68E-07
rs8042849-C	CHRNA	rs951266	chr15:78878541	0.829	Cigarettes per day	TAG	20418890	2010	3.00E-33
rs8042849-C	CHRNA	rs951266	chr15:78878541	0.829	Former smoker	TAG	20418890	2010	7.31E-06
rs8042849-C	CHRNA	rs16969968	chr15:78882925	0.829	Schizophrenia	PGC	25056061	2014	4.63E-07
rs8042849-C	CHRNA	rs16969968	chr15:78882925	0.829	Cigarettes per day	TAG	20418890	2010	4.48E-33
rs8042849-C	CHRNA	rs8192482	chr15:78886198	0.829	Schizophrenia	PGC	25056061	2014	5.13E-07
rs8042849-C	CHRNA	rs4887067	chr15:78886947	0.829	Schizophrenia	PGC	25056061	2014	5.06E-07
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Local histogram emphysema pattern	Castaldi PJ	25006744	2014	8.00E-13
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Local histogram emphysema pattern	Castaldi PJ	25006744	2014	5.00E-10
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	tery enlargement and chronic obstructive pulm	Lee JH	25101718	2015	7.00E-10
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Airflow obstruction	Wilk JB	22837378	2012	2.00E-07
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Lung cancer	Hung RJ	18385738	2008	1.58E-08
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	3.71E-64
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	1.00E-66
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Airflow obstruction all	Wilk JB	22837378	2012	1.91E-07
rs8042849-C	CHRNA	rs17486278	chr15:78867482	0.829	Airflow obstruction ever smokers	Wilk JB	22837378	2012	2.43E-08
rs8042849-C	CHRNA	rs7180002	chr15:78873993	0.829	Lung cancer	Hung RJ	18385738	2008	3.98E-08
rs8042849-C	CHRNA	rs7180002	chr15:78873993	0.829	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	5.83E-64
rs8042849-C	CHRNA	rs7180002	chr15:78873993	0.829	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	1.40E-66
rs8042849-C	CHRNA	rs7180002	chr15:78873993	0.829	Airflow obstruction all	Wilk JB	22837378	2012	2.23E-07
rs8042849-C	CHRNA	rs7180002	chr15:78873993	0.829	Airflow obstruction ever smokers	Wilk JB	22837378	2012	2.68E-08
rs8042849-C	CHRNA	rs951266	chr15:78878541	0.829	Lung cancer	Hung RJ	18385738	2008	7.94E-09
rs8042849-C	CHRNA	rs951266	chr15:78878541	0.829	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	3.19E-61
rs8042849-C	CHRNA	rs951266	chr15:78878541	0.829	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	1.40E-64
rs8042849-C	CHRNA	rs951266	chr15:78878541	0.829	Airflow obstruction all	Wilk JB	22837378	2012	3.64E-07
rs8042849-C	CHRNA	rs951266	chr15:78878541	0.829	Airflow obstruction ever smokers	Wilk JB	22837378	2012	3.47E-08
rs8042849-C	CHRNA	rs16969968	chr15:78882925	0.829	Nicotine dependence smoking cigarettes per da	David SP	22832964	2012	5.60E-72
rs8042849-C	CHRNA	rs16969968	chr15:78882925	0.829	Lung cancer	Hung RJ	18385738	2008	2.51E-09
rs8042849-C	CHRNA	rs16969968	chr15:78882925	0.829	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	4.29E-65
rs8042849-C	CHRNA	rs16969968	chr15:78882925	0.829	Chronic obstructive pulmonary disease COPD	Pillai SG	19300482	2009	2.78E-06
rs8042849-C	CHRNA	rs16969968	chr15:78882925	0.829	Nicotine dependence smoking cigarettes per da	TAG	20418890	2010	5.57E-72
rs8042849-C	CHRNA	rs16969968	chr15:78882925	0.829	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	7.00E-68
rs8042849-C	CHRNA	rs16969968	chr15:78882925	0.829	Airflow obstruction all	Wilk JB	22837378	2012	3.46E-07

rs8042849-C	CHRNA	rs16969968	chr15:78882925	0.829	Airflow obstruction ever smokers	Wilk JB	22837378	2012	3.47E-08
rs8042849-C	CHRNA	rs56390833	chr15:78877381	0.825	Schizophrenia	PGC	25056061	2014	6.55E-07
rs8042849-C	CHRNA	rs146009840	chr15:78906177	0.825	Schizophrenia	PGC	25056061	2014	9.14E-07
rs8042849-C	CHRNA	rs1317286	chr15:78896129	0.821	Schizophrenia	PGC	25056061	2014	1.36E-06
rs8042849-C	CHRNA	rs1317286	chr15:78896129	0.821	Cigarettes per day	TAG	20418890	2010	5.26E-33
rs8042849-C	CHRNA	rs1317286	chr15:78896129	0.821	Former smoker	TAG	20418890	2010	9.54E-06
rs8042849-C	CHRNA	rs1317286	chr15:78896129	0.821	Nicotine dependence smoking cigarettes per da	Berrettini	18227835	2008	2.60E-06
rs8042849-C	CHRNA	rs1317286	chr15:78896129	0.821	Lung cancer	Hung RJ	18385738	2008	2.51E-10
rs8042849-C	CHRNA	rs1317286	chr15:78896129	0.821	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	3.56E-65
rs8042849-C	CHRNA	rs1317286	chr15:78896129	0.821	Chronic obstructive pulmonary disease COPD	Pillai SG	19300482	2009	1.57E-06
rs8042849-C	CHRNA	rs1317286	chr15:78896129	0.821	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	6.20E-68
rs8042849-C	CHRNA	rs1317286	chr15:78896129	0.821	Airflow obstruction all	Wilk JB	22837378	2012	3.93E-07
rs8042849-C	CHRNA	rs1317286	chr15:78896129	0.821	Airflow obstruction ever smokers	Wilk JB	22837378	2012	4.74E-08
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Schizophrenia	PGC	25056061	2014	5.50E-07
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Cigarettes per day	TAG	20418890	2010	8.00E-33
rs8042849-C	CHRNA	rs55676755	chr15:78898932	0.817	Schizophrenia	PGC	25056061	2014	5.70E-07
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung adenocarcinoma	Landi MT	19836008	2009	2.00E-51
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung Neoplasms	Landi MT	19836008	2009	2.00E-51
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Smoking	Liu JZ	20418889	2010	2.00E-66
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Smoking behavior	Liu JZ	20418889	2010	2.00E-66
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	McKay JD	18978790	2008	1.00E-15
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung Neoplasms	McKay JD	18978790	2008	1.00E-15
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Smoking	TAG	20418890	2010	3.00E-73
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Smoking behavior	TAG	20418890	2010	3.00E-73
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Nicotine dependence	Thorgeirsson TE	18385739	2008	6.00E-20
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Smoking	Thorgeirsson TE	20418888	2010	2.00E-69
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Smoking behavior	Thorgeirsson TE	20418888	2010	2.00E-69
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Tobacco Use Disorder	Thorgeirsson TE	18385739	2008	6.00E-20
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	Amos CI	18385676	2008	7.00E-18
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	ng cancer in current smokers number of cigday	Amos CI	18385676	2008	1.33E-09
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer in smokers pack years 35	Amos CI	18385676	2008	3.57E-07
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer in smokers years smoked 35	Amos CI	18385676	2008	1.84E-09
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer in smokers years smoked 35	Amos CI	18385676	2008	2.62E-06
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Chronic obstructive pulmonary disease COPD	Brehm	21921092	2011	5.54E-07
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	Broderick P	19654303	2009	1.00E-25
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Nicotine dependence smoking cigarettes per da	Caporaso N	19247474	2009	5.00E-32
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Chronic obstructive pulmonary disease COPD	Cho MH	20173748	2010	3.99E-07
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Nicotine dependence smoking cigarettes per da	David SP	22832964	2012	2.80E-75
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer squamous cell carcinoma	Dong J	23341777	2013	7.10E-19
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	Hung RJ	18385738	2008	5.01E-09
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	Landi MT	19836008	2009	1.91E-51
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer adenocarcinoma	Landi MT	19836008	2009	7.10E-19
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer small cell carcinoma	Landi MT	19836008	2009	3.18E-09
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer squamous cell carcinoma	Landi MT	19836008	2009	1.01E-10
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Nicotine dependence smoking	Lettre G	21347282	2011	6.00E-20
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	1.71E-66

rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	Liu P	18780872	2008	2.84E-08
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	McKay JD	18978790	2008	7.00E-16
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Chronic obstructive pulmonary disease COPD	Pillai SG	19300482	2009	6.56E-11
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Chronic obstructive pulmonary disease COPD	Qiu	21949713	2011	2.80E-06
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	Soler Artigas M	21946350	2011	1.91E-51
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Nicotine dependence smoking cigarettes per da	TAG	20418890	2010	2.75E-73
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	Thorgeirsson TE	18385739	2008	1.50E-08
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer females	Thorgeirsson TE	18385739	2008	8.30E-06
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Nicotine dependence smoking	Thorgeirsson TE	18385739	2008	6.70E-14
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	:e smoking 4 on Fagerstrom Test andor 3 or mo	Thorgeirsson TE	20418888	2010	1.30E-09
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	2.40E-69
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Nicotine dependence smoking quantity	Thorgeirsson TE	18385739	2008	5.00E-16
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Peripheral arterial disease PAD	Thorgeirsson TE	18385739	2008	1.40E-07
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	Timofeeva MN	22899653	2012	2.20E-63
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer adenocarcinoma	Timofeeva MN	22899653	2012	7.00E-29
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer age 50	Timofeeva MN	22899653	2012	1.20E-09
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer age 50	Timofeeva MN	22899653	2012	8.10E-48
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer females	Timofeeva MN	22899653	2012	5.70E-25
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer in current smokers	Timofeeva MN	22899653	2012	3.60E-36
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer in ever smokers	Timofeeva MN	22899653	2012	1.80E-59
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer in former smokers	Timofeeva MN	22899653	2012	8.10E-19
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer large cell carcinoma	Timofeeva MN	22899653	2012	4.70E-06
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer males	Timofeeva MN	22899653	2012	9.10E-30
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer non small cell lung cancer stage 12	Timofeeva MN	22899653	2012	3.70E-12
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer non small cell lung cancer stage 34	Timofeeva MN	22899653	2012	1.50E-29
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer small cell carcinoma	Timofeeva MN	22899653	2012	3.40E-14
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer squamous cell carcinoma	Timofeeva MN	22899653	2012	7.20E-22
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer with family history	Timofeeva MN	22899653	2012	1.40E-11
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer with no family history	Timofeeva MN	22899653	2012	5.00E-43
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Lung cancer	Wang Y	18978787	2008	2.82E-19
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Airflow obstruction all	Wilk JB	22837378	2012	3.29E-07
rs8042849-C	CHRNA	rs1051730	chr15:78894339	0.817	Airflow obstruction ever smokers	Wilk JB	22837378	2012	3.36E-08
rs8042849-C	CHRNA	rs141518190	chr15:78900647	0.813	Schizophrenia	PGC	25056061	2014	9.41E-07
rs8042849-C	CHRNA	rs147499554	chr15:78900650	0.813	Schizophrenia	PGC	25056061	2014	9.43E-07
rs8042849-C	CHRNA	rs138544659	chr15:78900701	0.813	Schizophrenia	PGC	25056061	2014	4.36E-07
rs8042849-C	CHRNA	rs147144681	chr15:78900908	0.813	Schizophrenia	PGC	25056061	2014	2.80E-08
rs8042849-C	CHRNA	rs114205691	chr15:78901113	0.813	Local histogram emphysema pattern	Castaldi PJ	25006744	2014	9.00E-11
rs8042849-C	CHRNA	rs114205691	chr15:78901113	0.813	Local histogram emphysema pattern	Castaldi PJ	25006744	2014	3.00E-13
rs8042849-C	CHRNA	rs56077333	chr15:78899003	0.806	Schizophrenia	PGC	25056061	2014	1.32E-06
rs8042849-C	CHRNA	rs4243084	chr15:78911672	0.802	Schizophrenia	PGC	25056061	2014	9.06E-06
rs8042849-C	CHRNA	rs2568494	chr15:78740964	0.746	Cigarettes per day	TAG	20418890	2010	3.39E-24
rs8042849-C	CHRNA	rs2656052	chr15:78740932	0.746	Cigarettes per day	TAG	20418890	2010	3.76E-24
rs8042849-C	CHRNA	rs2568494	chr15:78740964	0.746	Lung cancer	Hung RJ	18385738	2008	1.26E-09
rs8042849-C	CHRNA	rs2568494	chr15:78740964	0.746	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	1.61E-49
rs8042849-C	CHRNA	rs2568494	chr15:78740964	0.746	Nicotine dependence smoking cigarettes per da	Soler Artigas M	21946350	2011	2.15E-15
rs8042849-C	CHRNA	rs2568494	chr15:78740964	0.746	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	2.00E-51

rs8042849-C	CHRNA	rs2656052	chr15:78740932	0.746	Lung cancer	Hung RJ	18385738	2008	2.51E-10
rs8042849-C	CHRNA	rs2656052	chr15:78740932	0.746	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	5.57E-49
rs8042849-C	CHRNA	rs2656052	chr15:78740932	0.746	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	2.70E-51
rs8042849-C	CHRNA	rs8039449	chr15:78914534	0.744	Schizophrenia	PGC	25056061	2014	7.62E-06
rs8042849-C	CHRNA	rs55958997	chr15:78915872	0.744	Exhaled carbon monoxide levels	Bloom AJ	25072098	2014	2.00E-09
rs8042849-C	CHRNA	rs7181486	chr15:78741618	0.739	Cigarettes per day	TAG	20418890	2010	2.46E-24
rs8042849-C	CHRNA	rs17483721	chr15:78733731	0.739	Cigarettes per day	TAG	20418890	2010	7.34E-24
rs8042849-C	CHRNA	rs7181486	chr15:78741618	0.739	rtery enlargement in chronic obstructive pulmo	Lee JH	25101718	2015	2.00E-08
rs8042849-C	CHRNA	rs7181486	chr15:78741618	0.739	Lung cancer	Hung RJ	18385738	2008	3.16E-08
rs8042849-C	CHRNA	rs7181486	chr15:78741618	0.739	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	1.48E-49
rs8042849-C	CHRNA	rs7181486	chr15:78741618	0.739	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	1.70E-51
rs8042849-C	CHRNA	rs17483721	chr15:78733731	0.739	Lung cancer	Hung RJ	18385738	2008	1.58E-07
rs8042849-C	CHRNA	rs17483721	chr15:78733731	0.739	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	7.01E-49
rs8042849-C	CHRNA	rs17483721	chr15:78733731	0.739	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	9.10E-51
rs8042849-C	CHRNA	rs17483929	chr15:78742376	0.735	Cigarettes per day	TAG	20418890	2010	2.70E-24
rs8042849-C	CHRNA	rs17483929	chr15:78742376	0.735	Lung cancer	Hung RJ	18385738	2008	5.01E-08
rs8042849-C	CHRNA	rs17483929	chr15:78742376	0.735	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	2.73E-49
rs8042849-C	CHRNA	rs17483929	chr15:78742376	0.735	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	6.00E-51
rs8042849-C	CHRNA	rs2009746	chr15:78754102	0.735	Cigarettes per day	TAG	20418890	2010	1.52E-25
rs8042849-C	CHRNA	rs2009746	chr15:78754102	0.735	Lung cancer	Hung RJ	18385738	2008	3.16E-08
rs8042849-C	CHRNA	rs2009746	chr15:78754102	0.735	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	1.67E-51
rs8042849-C	CHRNA	rs2009746	chr15:78754102	0.735	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	2.70E-53
rs8042849-C	CHRNA	rs2656065	chr15:78750549	0.732	Cigarettes per day	TAG	20418890	2010	4.88E-25
rs8042849-C	CHRNA	rs2656065	chr15:78750549	0.732	Lung cancer	Hung RJ	18385738	2008	3.98E-08
rs8042849-C	CHRNA	rs2656065	chr15:78750549	0.732	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	1.04E-50
rs8042849-C	CHRNA	rs2656065	chr15:78750549	0.732	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	1.20E-52
rs8042849-C	CHRNA	rs72743158	chr15:78926445	0.726	Schizophrenia	PGC	25056061	2014	2.30E-06
rs8042849-C	CHRNA	rs2869548	chr15:78922638	0.725	Schizophrenia	PGC	25056061	2014	1.13E-06
rs8042849-C	CHRNA	rs17487223	chr15:78923987	0.725	Schizophrenia	PGC	25056061	2014	1.22E-06
rs8042849-C	CHRNA	rs17487223	chr15:78923987	0.725	Cigarettes per day	TAG	20418890	2010	4.23E-29
rs8042849-C	CHRNA	rs17487223	chr15:78923987	0.725	Lung cancer	Hung RJ	18385738	2008	1.00E-07
rs8042849-C	CHRNA	rs17487223	chr15:78923987	0.725	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	3.18E-58
rs8042849-C	CHRNA	rs17487223	chr15:78923987	0.725	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	3.90E-61
rs8042849-C	CHRNA	rs17484524	chr15:78772676	0.717	Cigarettes per day	TAG	20418890	2010	2.01E-26
rs8042849-C	CHRNA	rs17484235	chr15:78761414	0.717	Cigarettes per day	TAG	20418890	2010	1.14E-25
rs8042849-C	CHRNA	rs17405217	chr15:78731149	0.717	Cigarettes per day	TAG	20418890	2010	9.09E-24
rs8042849-C	CHRNA	rs17483548	chr15:78730313	0.717	Cigarettes per day	TAG	20418890	2010	9.66E-24
rs8042849-C	CHRNA	rs17484524	chr15:78772676	0.717	Lung cancer	Hung RJ	18385738	2008	2.00E-08
rs8042849-C	CHRNA	rs17484524	chr15:78772676	0.717	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	1.44E-52
rs8042849-C	CHRNA	rs17484524	chr15:78772676	0.717	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	2.00E-54
rs8042849-C	CHRNA	rs17484235	chr15:78761414	0.717	Lung cancer	Hung RJ	18385738	2008	2.51E-09
rs8042849-C	CHRNA	rs17484235	chr15:78761414	0.717	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	4.38E-51
rs8042849-C	CHRNA	rs17484235	chr15:78761414	0.717	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	5.20E-41
rs8042849-C	CHRNA	rs17405217	chr15:78731149	0.717	Lung cancer	Hung RJ	18385738	2008	5.01E-08
rs8042849-C	CHRNA	rs17405217	chr15:78731149	0.717	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	2.09E-48
rs8042849-C	CHRNA	rs17405217	chr15:78731149	0.717	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	2.50E-50

rs8042849-C	CHRNA	rs17483548	chr15:78730313	0.717	Lung cancer	Hung RJ	18385738	2008	2.51E-08
rs8042849-C	CHRNA	rs17483548	chr15:78730313	0.717	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	4.93E-48
rs8042849-C	CHRNA	rs17483548	chr15:78730313	0.717	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	6.30E-50
rs8042849-C	CHRNA	rs11858836	chr15:78783277	0.707	Chronic obstructive pulmonary disease	Cho MH	22080838	2011	1.00E-06
rs8042849-C	CHRNA	rs11858836	chr15:78783277	0.707	Pulmonary Disease Chronic Obstructive	Cho MH	22080838	2011	1.00E-06
rs8042849-C	CHRNA	rs11858836	chr15:78783277	0.707	Chronic obstructive pulmonary disease COPD	Cho MH	22080838	2011	1.35E-06
rs8042849-C	CHRNA	rs951985	chr15:78720923	0.707	Schizophrenia	PGC	25056061	2014	1.94E-06
rs8042849-C	CHRNA	rs1504550	chr15:78766250	0.703	Cigarettes per day	TAG	20418890	2010	4.53E-26
rs8042849-C	CHRNA	rs1504550	chr15:78766250	0.703	Lung cancer	Hung RJ	18385738	2008	3.16E-08
rs8042849-C	CHRNA	rs1504550	chr15:78766250	0.703	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	3.28E-52
rs8042849-C	CHRNA	rs1504550	chr15:78766250	0.703	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	5.10E-54
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Schizophrenia	PGC	25056061	2014	2.15E-06
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Cigarettes per day	TAG	20418890	2010	4.23E-35
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Former smoker	TAG	20418890	2010	1.82E-06
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	ic obstructive pulmonary disease moderate to s	Cho MH	24621683	2014	6.00E-14
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Chronic obstructive pulmonary disease severe	Cho MH	24621683	2014	3.00E-16
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Serum albumin level	Franceschini N	23022100	2012	6.00E-07
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	c bronchitis and chronic obstructive pulmonary	Lee JH	25241909	2014	3.00E-06
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	c bronchitis and chronic obstructive pulmonary	Lee JH	25241909	2014	2.00E-08
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Chronic obstructive pulmonary disease	Lee JH	25101718	2015	6.00E-07
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Pulmonary function	Soler Artigas M	21946350	2011	5.00E-07
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Respiratory Function Tests	Soler Artigas M	21946350	2011	5.00E-07
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Chronic obstructive pulmonary disease COPD	Brehm	21921092	2011	2.81E-07
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Lung cancer	Broderick P	19654303	2009	3.19E-16
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Lung cancer squamous cell carcinoma	Dong J	23341777	2013	3.32E-18
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Serum albumin	Franceschini N	23022100	2012	6.20E-07
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Lung cancer	Landi MT	19836008	2009	2.75E-38
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Lung cancer adenocarcinoma	Landi MT	19836008	2009	3.32E-18
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Lung cancer small cell carcinoma	Landi MT	19836008	2009	2.31E-09
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Lung cancer squamous cell carcinoma	Landi MT	19836008	2009	8.72E-13
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	7.83E-66
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	function forced expiratory volume in 1 second	Soler Artigas M	21946350	2011	4.72E-07
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Nicotine dependence smoking cigarettes per da	TAG	20418890	2010	4.20E-35
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	6.70E-69
rs8042849-C	CHRNA	rs12914385	chr15:78898723	0.696	Lung cancer	Timofeeva MN	22899653	2012	2.80E-28
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	Schizophrenia	PGC	25056061	2014	5.40E-06
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	Cigarettes per day	TAG	20418890	2010	4.03E-08
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	Obesity related traits	Comuzzie AG	23251661	2012	6.00E-08
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	Pulmonary function interaction	Hancock DB	23284291	2012	7.00E-07
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	Pulmonary function interaction	Hancock DB	23284291	2012	9.00E-08
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	ep energy expenditure adj weight kcald in child	Comuzzie AG	23251661	2012	5.95E-08
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	forced expiratory volume in 1 second FEV1 smol	Hancock DB	23284291	2012	7.29E-07
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	ory volume in 1 second FEV1 to forced vital capa	Hancock DB	23284291	2012	9.03E-08
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	Nicotine dependence smoking cigarettes per da	Liu JZ	20418889	2010	5.90E-44
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	function forced expiratory volume in 1 second	Soler Artigas M	21946350	2011	2.98E-06
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	d expiratory volume in 1 second FEV1 to forced	Soler Artigas M	21946350	2011	1.14E-06

rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	Nicotine dependence smoking cigarettes per da	Soler Artigas M	21946350	2011	2.53E-17
rs8042849-C	CHRNA	rs8040868	chr15:78911181	0.679	Nicotine dependence smoking cigarettes per da	Thorgeirsson TE	20418888	2010	5.80E-50
rs8042849-C	CHRNA	rs10851907	chr15:78915864	0.633	Schizophrenia	PGC	25056061	2014	2.24E-06
rs8042849-C	CHRNA	rs55988292	chr15:78936168	0.609	Schizophrenia	PGC	25056061	2014	8.78E-06
rs34831921-C	HLA	rs34831921	chr6:32590768	1	Rheumatoid arthritis	Okada Y	24390342	2014	6.60E-25
rs34831921-C	HLA	rs34831921	chr6:32590768	1	Rheumatoid arthritis	Okada Y	24390342	2014	3.30E-84
rs34831921-C	HLA	rs34831921	chr6:32590768	1	Rheumatoid arthritis	Okada Y	24390342	2014	3.30E-97
rs34831921-C	HLA	rs34915133	chr6:32591422	0.989	Rheumatoid arthritis	Okada Y	24390342	2014	8.80E-25
rs34831921-C	HLA	rs34915133	chr6:32591422	0.989	Rheumatoid arthritis	Okada Y	24390342	2014	1.10E-83
rs34831921-C	HLA	rs34915133	chr6:32591422	0.989	Rheumatoid arthritis	Okada Y	24390342	2014	4.60E-97
rs34831921-C	HLA	rs73728618	chr6:32591567	0.989	Rheumatoid arthritis	Okada Y	24390342	2014	8.60E-25
rs34831921-C	HLA	rs73728618	chr6:32591567	0.989	Rheumatoid arthritis	Okada Y	24390342	2014	1.10E-83
rs34831921-C	HLA	rs73728618	chr6:32591567	0.989	Rheumatoid arthritis	Okada Y	24390342	2014	4.50E-97
rs34831921-C	HLA	rs34720986	chr6:32593270	0.989	Rheumatoid arthritis	Okada Y	24390342	2014	3.90E-25
rs34831921-C	HLA	rs34720986	chr6:32593270	0.989	Rheumatoid arthritis	Okada Y	24390342	2014	2.00E-82
rs34831921-C	HLA	rs34720986	chr6:32593270	0.989	Rheumatoid arthritis	Okada Y	24390342	2014	1.70E-96
rs34831921-C	HLA	rs113705304	chr6:32590453	0.977	Rheumatoid arthritis	Okada Y	24390342	2014	6.80E-25
rs34831921-C	HLA	rs113705304	chr6:32590453	0.977	Rheumatoid arthritis	Okada Y	24390342	2014	3.30E-84
rs34831921-C	HLA	rs113705304	chr6:32590453	0.977	Rheumatoid arthritis	Okada Y	24390342	2014	3.40E-97
rs34831921-C	HLA	rs35508382	chr6:32593144	0.977	Rheumatoid arthritis	Okada Y	24390342	2014	1.70E-25
rs34831921-C	HLA	rs35508382	chr6:32593144	0.977	Rheumatoid arthritis	Okada Y	24390342	2014	1.80E-82
rs34831921-C	HLA	rs35508382	chr6:32593144	0.977	Rheumatoid arthritis	Okada Y	24390342	2014	1.50E-96
rs34831921-C	HLA	rs34967069	chr6:32591248	0.966	Rheumatoid arthritis	Okada Y	24390342	2014	1.00E-24
rs34831921-C	HLA	rs34967069	chr6:32591248	0.966	Rheumatoid arthritis	Okada Y	24390342	2014	7.70E-84
rs34831921-C	HLA	rs34967069	chr6:32591248	0.966	Rheumatoid arthritis	Okada Y	24390342	2014	4.30E-97
rs34831921-C	HLA	rs35001273	chr6:32591664	0.966	Rheumatoid arthritis	Okada Y	24390342	2014	1.20E-24
rs34831921-C	HLA	rs35001273	chr6:32591664	0.966	Rheumatoid arthritis	Okada Y	24390342	2014	2.00E-82
rs34831921-C	HLA	rs35001273	chr6:32591664	0.966	Rheumatoid arthritis	Okada Y	24390342	2014	2.20E-96
rs34831921-C	HLA	rs35867827	chr6:32592068	0.966	Rheumatoid arthritis	Okada Y	24390342	2014	7.20E-25
rs34831921-C	HLA	rs35867827	chr6:32592068	0.966	Rheumatoid arthritis	Okada Y	24390342	2014	2.10E-82
rs34831921-C	HLA	rs35867827	chr6:32592068	0.966	Rheumatoid arthritis	Okada Y	24390342	2014	6.30E-96
rs34831921-C	HLA	rs35224566	chr6:32592313	0.944	Rheumatoid arthritis	Okada Y	24390342	2014	5.60E-25
rs34831921-C	HLA	rs35224566	chr6:32592313	0.944	Rheumatoid arthritis	Okada Y	24390342	2014	2.10E-82
rs34831921-C	HLA	rs35224566	chr6:32592313	0.944	Rheumatoid arthritis	Okada Y	24390342	2014	4.50E-96
rs34831921-C	HLA	rs78503004	chr6:32594103	0.944	Rheumatoid arthritis	Okada Y	24390342	2014	1.40E-25
rs34831921-C	HLA	rs78503004	chr6:32594103	0.944	Rheumatoid arthritis	Okada Y	24390342	2014	1.40E-82
rs34831921-C	HLA	rs78503004	chr6:32594103	0.944	Rheumatoid arthritis	Okada Y	24390342	2014	1.20E-96
rs34831921-C	HLA	rs28584179	chr6:32626119	0.944	Rheumatoid arthritis	Okada Y	24390342	2014	2.60E-68
rs34831921-C	HLA	rs28584179	chr6:32626119	0.944	Rheumatoid arthritis	Okada Y	24390342	2014	2.20E-68
rs34831921-C	HLA	rs114786106	chr6:32596878	0.932	Rheumatoid arthritis	Okada Y	24390342	2014	1.70E-25
rs34831921-C	HLA	rs114786106	chr6:32596878	0.932	Rheumatoid arthritis	Okada Y	24390342	2014	3.60E-80
rs34831921-C	HLA	rs114786106	chr6:32596878	0.932	Rheumatoid arthritis	Okada Y	24390342	2014	1.50E-93
rs34831921-C	HLA	rs73728889	chr6:32596856	0.921	Rheumatoid arthritis	Okada Y	24390342	2014	1.90E-25
rs34831921-C	HLA	rs73728889	chr6:32596856	0.921	Rheumatoid arthritis	Okada Y	24390342	2014	1.30E-82
rs34831921-C	HLA	rs73728889	chr6:32596856	0.921	Rheumatoid arthritis	Okada Y	24390342	2014	5.60E-97
rs34831921-C	HLA	rs73730377	chr6:32584880	0.841	Rheumatoid arthritis	Okada Y	24390342	2014	5.00E-84

rs34831921-C	HLA	rs73730377	chr6:32584880	0.841	Rheumatoid arthritis	Okada Y	24390342	2014	2.20E-96
rs34831921-C	HLA	rs73730372	chr6:32584581	0.841	Rheumatoid arthritis	Okada Y	24390342	2014	2.20E-83
rs34831921-C	HLA	rs73730372	chr6:32584581	0.841	Rheumatoid arthritis	Okada Y	24390342	2014	2.30E-96
rs34831921-C	HLA	rs113016235	chr6:32584977	0.832	Rheumatoid arthritis	Okada Y	24390342	2014	8.40E-85
rs34831921-C	HLA	rs113016235	chr6:32584977	0.832	Rheumatoid arthritis	Okada Y	24390342	2014	1.90E-97
rs34831921-C	HLA	rs115625939	chr6:32583584	0.827	Rheumatoid arthritis	Okada Y	24390342	2014	2.20E-84
rs34831921-C	HLA	rs115625939	chr6:32583584	0.827	Rheumatoid arthritis	Okada Y	24390342	2014	7.60E-97
rs34831921-C	HLA	rs113243185	chr6:32585071	0.816	Rheumatoid arthritis	Okada Y	24390342	2014	1.90E-84
rs34831921-C	HLA	rs113243185	chr6:32585071	0.816	Rheumatoid arthritis	Okada Y	24390342	2014	3.80E-97
rs34831921-C	HLA	rs62406305	chr6:32585371	0.745	Rheumatoid arthritis	Okada Y	24390342	2014	3.70E-92
rs34831921-C	HLA	rs62406305	chr6:32585371	0.745	Rheumatoid arthritis	Okada Y	24390342	2014	6.00E-104
rs34831921-C	HLA	rs10947290	chr6:32446269	0.668	Crohns disease	IBDGC	26192919	2015	1.33E-04
rs34831921-C	HLA	rs10947290	chr6:32446269	0.668	Rheumatoid arthritis	Okada Y	24390342	2014	2.30E-49
rs34831921-C	HLA	rs10947290	chr6:32446269	0.668	Rheumatoid arthritis	Okada Y	24390342	2014	3.60E-58
rs34831921-C	HLA	rs28688825	chr6:32587157	0.655	Rheumatoid arthritis	Okada Y	24390342	2014	5.20E-31
rs34831921-C	HLA	rs28688825	chr6:32587157	0.655	Rheumatoid arthritis	Okada Y	24390342	2014	1.10E-66
rs34831921-C	HLA	rs28688825	chr6:32587157	0.655	Rheumatoid arthritis	Okada Y	24390342	2014	1.80E-92
rs429358-C	APOE	rs429358	chr19:45411941	1	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	2.17E-09
rs429358-C	APOE	rs429358	chr19:45411941	1	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	1.37E-08
rs429358-C	APOE	rs429358	chr19:45411941	1	Alzheimers disease	IGAP	24162737	2013	6.70e-536
rs429358-C	APOE	rs429358	chr19:45411941	1	Lewy body disease	Beecham GW	25188341	2014	5.00E-12
rs429358-C	APOE	rs429358	chr19:45411941	1	Lewy body disease	Beecham GW	25188341	2014	3.00E-11
rs429358-C	APOE	rs429358	chr19:45411941	1	Lewy body disease	Beecham GW	25188341	2014	1.00E-12
rs429358-C	APOE	rs429358	chr19:45411941	1	Alzheimer Disease	Kim S	21123754	2010	1.00E-06
rs429358-C	APOE	rs429358	chr19:45411941	1	Alzheimers disease biomarkers	Kim S	21123754	2010	1.00E-06
rs429358-C	APOE	rs429358	chr19:45411941	1	Alzheimers disease biomarkers	Ramanan VK	23419831	2013	5.00E-14
rs429358-C	APOE	rs429358	chr19:45411941	1	rospinal AB1 42 levels in Alzheimers disease der	Ramirez A	25027320	2014	4.00E-17
rs429358-C	APOE	rs429358	chr19:45411941	1	Age related macular degeneration	Cipriani V	22694956	2012	2.80E-06
rs429358-C	APOE	rs429358	chr19:45411941	1	Cognitive ageing	Davies G	23207651	2012	3.66E-11
rs429358-C	APOE	rs429358	chr19:45411941	1	Cognitive ageing females	Davies G	23207651	2012	1.19E-11
rs429358-C	APOE	rs429358	chr19:45411941	1	APOE apolipoprotein E	Deelen J	21418511	2011	7.42E-28
rs429358-C	APOE	rs429358	chr19:45411941	1	APOE apolipoprotein E females	Deelen J	21418511	2011	1.13E-22
rs429358-C	APOE	rs429358	chr19:45411941	1	APOE apolipoprotein E males	Deelen J	21418511	2011	2.74E-11
rs429358-C	APOE	rs429358	chr19:45411941	1	LDL cholesterol	Deelen J	21418511	2011	4.91E-05
rs429358-C	APOE	rs429358	chr19:45411941	1	Total cholesterol	Deelen J	21418511	2011	1.00E-03
rs429358-C	APOE	rs429358	chr19:45411941	1	Late onset Alzheimers disease	Gaj	22785395	2012	1.02E-06
rs429358-C	APOE	rs429358	chr19:45411941	1	Late onset Alzheimers disease	Hu X	21390209	2011	2.74E-78
rs429358-C	APOE	rs429358	chr19:45411941	1	ıbundance pQTL of APOE UniProtP02649Peptid	Johnansson	23487758	2013	3.90E-12
rs429358-C	APOE	rs429358	chr19:45411941	1	Alzheimers disease age of onset	Kamboh MI	22005931	2011	3.37E-18
rs429358-C	APOE	rs429358	chr19:45411941	1	Late onset Alzheimers disease	Naj AC	20885792	2010	5.49E-58
rs429358-C	APOE	rs429358	chr19:45411941	1	Alzheimers disease	Potkin SG	19668339	2009	2.30E-16
rs429358-C	APOE	rs429358	chr19:45411941	1	Cortical amyloid beta load	Ramanan VK	23419831	2013	5.45E-14
rs429358-C	APOE	rs429358	chr19:45411941	1	Late onset Alzheimers disease	Reitz C	23571587	2013	5.50E-47
rs429358-C	APOE	rs429358	chr19:45411941	1	LDL cholesterol change with statins	Thompson	20031582	2009	4.21E-10
rs429358-C	APOE	rs429358	chr19:45411941	1	LDL cholesterol female	Wu Y	21647738	2011	2.30E-07
rs429358-C	APOE	rs429358	chr19:45411941	1	Plasma C reactive protein female	Wu Y	21647738	2011	1.00E-04

rs429358-C	APOE	rs429358	chr19:45411941	1	Total cholesterol females	Wu Y	21647738	2011	2.70E-05
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	6.13E-08
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	3.01E-06
rs429358-C	APOE	rs769449	chr19:45410002	0.766	BMI	GIANT	25673413	2015	1.29E-06
rs429358-C	APOE	rs769449	chr19:45410002	0.766	BMI	GIANT	25673413	2015	4.43E-07
rs429358-C	APOE	rs769449	chr19:45410002	0.766	BMI in males	GIANT	25673413	2015	2.40E-05
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Hip circumference	GIANT	25673412	2015	3.60E-04
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Hip circumference	GIANT	25673412	2015	3.10E-04
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Waist circumference	GIANT	25673412	2015	1.50E-07
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Waist circumference	GIANT	25673412	2015	1.70E-07
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Waist circumference in males	GIANT	25673412	2015	1.30E-04
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Waist hip ratio	GIANT	25673412	2015	4.00E-08
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Waist hip ratio	GIANT	25673412	2015	9.60E-08
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Waist hip ratio adjusted for BMI	GIANT	25673412	2015	4.50E-04
rs429358-C	APOE	rs769449	chr19:45410002	0.766	HDL	GLGC	24097068	2013	6.79E-17
rs429358-C	APOE	rs769449	chr19:45410002	0.766	LDL	GLGC	24097068	2013	4.90E-161
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Total cholesterol	GLGC	24097068	2013	6.77E-103
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Triglycerides	GLGC	24097068	2013	3.15E-09
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Alzheimers disease	IGAP	24162737	2013	9.86e-523
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Alzheimers disease biomarkers	Cruchaga C	23562540	2013	2.00E-18
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Alzheimers disease biomarkers	Cruchaga C	23562540	2013	2.00E-16
rs429358-C	APOE	rs769449	chr19:45410002	0.766	C reactive protein	Ridker PM	18439548	2008	9.00E-21
rs429358-C	APOE	rs769449	chr19:45410002	0.766	C Reactive Protein	Ridker PM	18439548	2008	9.00E-21
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Cognitive decline age related	Zhang C	24468470	2013	5.00E-19
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Total cholesterol	Asselbergs	23063622	2012	5.10E-07
rs429358-C	APOE	rs769449	chr19:45410002	0.766	APOB apolipoprotein B	Chasman	19802338	2008	2.40E-16
rs429358-C	APOE	rs769449	chr19:45410002	0.766	APOA1 assay lipoprotein fraction concentration	Chasman DI	19936222	2009	2.80E-11
rs429358-C	APOE	rs769449	chr19:45410002	0.766	ssay lipoprotein fraction concentration in fastin	Chasman DI	19936222	2009	1.10E-11
rs429358-C	APOE	rs769449	chr19:45410002	0.766	;say lipoprotein fraction concentration in fasting	Chasman DI	19936222	2009	1.10E-36
rs429358-C	APOE	rs769449	chr19:45410002	0.766	DL cholesterol lipoprotein fraction concentratic	Chasman DI	19936222	2009	2.19E-11
rs429358-C	APOE	rs769449	chr19:45410002	0.766	holesterol lipoprotein fraction concentration by	Chasman DI	19936222	2009	2.20E-12
rs429358-C	APOE	rs769449	chr19:45410002	0.766	ol lipoprotein fraction concentration by NMR in	Chasman DI	19936222	2009	2.36E-11
rs429358-C	APOE	rs769449	chr19:45410002	0.766	sterol lipoprotein fraction concentration in fasti	Chasman DI	19936222	2009	2.30E-10
rs429358-C	APOE	rs769449	chr19:45410002	0.766	olesterol mean size lipoprotein fraction concen	Chasman DI	19936222	2009	1.49E-09
rs429358-C	APOE	rs769449	chr19:45410002	0.766	cholesterol small lipoprotein fraction concentra	Chasman DI	19936222	2009	7.00E-27
rs429358-C	APOE	rs769449	chr19:45410002	0.766	rol small lipoprotein fraction concentration in fa	Chasman DI	19936222	2009	1.37E-21
rs429358-C	APOE	rs769449	chr19:45410002	0.766	cholesterol total lipoprotein fraction concentra	Chasman DI	19936222	2009	1.10E-44
rs429358-C	APOE	rs769449	chr19:45410002	0.766	rol total lipoprotein fraction concentration in fa	Chasman DI	19936222	2009	1.70E-33
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Cerebrospinal fluid CSF amyloid beta Ab42	Cruchaga C	23562540	2013	9.02E-47
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Cerebrospinal fluid CSF ptau	Cruchaga C	23562540	2013	2.10E-18
rs429358-C	APOE	rs769449	chr19:45410002	0.766	nal fluid CSF ptau in patients with clinical demer	Cruchaga C	23562540	2013	1.54E-06
rs429358-C	APOE	rs769449	chr19:45410002	0.766	nal fluid CSF ptau in patients with clinical demer	Cruchaga C	23562540	2013	3.38E-06
rs429358-C	APOE	rs769449	chr19:45410002	0.766	inal fluid CSF ptau in patients with high amyloid	Cruchaga C	23562540	2013	7.98E-05
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Cerebrospinal fluid CSF tau	Cruchaga C	23562540	2013	1.95E-16
rs429358-C	APOE	rs769449	chr19:45410002	0.766	inal fluid CSF tau in patients with clinical demen	Cruchaga C	23562540	2013	1.77E-05
rs429358-C	APOE	rs769449	chr19:45410002	0.766	inal fluid CSF tau in patients with clinical demen	Cruchaga C	23562540	2013	4.86E-04

rs429358-C	APOE	rs769449	chr19:45410002	0.766	inal fluid CSF tau in patients with high amyloid	Cruchaga C	23562540	2013	6.58E-05
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Cognitive ageing	Davies G	23207651	2012	2.51E-10
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Cognitive ageing females	Davies G	23207651	2012	1.62E-10
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Generalized vitiligo	Jin Y	22561518	2012	1.81E-07
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum ApoB	Kettunen J	22286219	2012	1.03E-13
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum Est C	Kettunen J	22286219	2012	4.42E-12
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum IDL C	Kettunen J	22286219	2012	2.05E-13
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum IDL C eFR	Kettunen J	22286219	2012	9.80E-13
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum IDL FC	Kettunen J	22286219	2012	1.22E-12
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum IDL L	Kettunen J	22286219	2012	7.99E-13
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum IDL P	Kettunen J	22286219	2012	3.46E-12
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum IDL PL	Kettunen J	22286219	2012	5.10E-13
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum LA	Kettunen J	22286219	2012	1.75E-12
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum LDL C	Kettunen J	22286219	2012	3.59E-22
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum LDL C eFR	Kettunen J	22286219	2012	5.43E-15
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum L LDL C	Kettunen J	22286219	2012	5.25E-20
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum L LDL CE	Kettunen J	22286219	2012	2.20E-19
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum L LDL FC	Kettunen J	22286219	2012	4.43E-20
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum L LDL L	Kettunen J	22286219	2012	1.28E-19
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum L LDL P	Kettunen J	22286219	2012	3.19E-19
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum L LDL PL	Kettunen J	22286219	2012	4.80E-18
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum M HDL LS HDL L	Kettunen J	22286219	2012	2.71E-13
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum M LDL C	Kettunen J	22286219	2012	5.14E-23
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum M LDL CE	Kettunen J	22286219	2012	1.12E-21
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum M LDL CM LDL PL	Kettunen J	22286219	2012	3.05E-25
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum M LDL L	Kettunen J	22286219	2012	9.94E-23
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum M LDL P	Kettunen J	22286219	2012	3.30E-22
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum M LDL PL	Kettunen J	22286219	2012	1.01E-18
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum Serum C	Kettunen J	22286219	2012	3.59E-12
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum S LDL C	Kettunen J	22286219	2012	1.43E-23
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum S LDL L	Kettunen J	22286219	2012	3.08E-23
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum S LDL P	Kettunen J	22286219	2012	3.42E-21
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Serum Tot C	Kettunen J	22286219	2012	5.00E-12
rs429358-C	APOE	rs769449	chr19:45410002	0.766	Plasma C reactive protein female	Ridker PM	18439548	2008	8.90E-21
rs429358-C	APOE	rs10414043	chr19:45415713	0.759	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	2.23E-08
rs429358-C	APOE	rs10414043	chr19:45415713	0.759	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	3.83E-07
rs429358-C	APOE	rs10414043	chr19:45415713	0.759	Alzheimers disease	IGAP	24162737	2013	1.15e-522
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	1.78E-08
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	2.91E-07
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	HDL	GLGC	24097068	2013	2.58E-06
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Total cholesterol	GLGC	24097068	2013	2.82E-58
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Alzheimers disease	IGAP	24162737	2013	1.80e-520
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum ApoB	Kettunen J	22286219	2012	7.40E-14
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum Est C	Kettunen J	22286219	2012	1.98E-12
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum IDL C	Kettunen J	22286219	2012	3.30E-14
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum IDL C eFR	Kettunen J	22286219	2012	1.21E-12

rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum IDL FC	Kettunen J	22286219	2012	2.13E-13
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum IDL L	Kettunen J	22286219	2012	1.33E-13
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum IDL P	Kettunen J	22286219	2012	6.72E-13
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum IDL PL	Kettunen J	22286219	2012	1.01E-13
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum LA	Kettunen J	22286219	2012	2.92E-12
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum LDL C	Kettunen J	22286219	2012	2.03E-22
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum LDL C eFR	Kettunen J	22286219	2012	9.38E-16
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum L LDL C	Kettunen J	22286219	2012	1.88E-20
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum L LDL CE	Kettunen J	22286219	2012	8.64E-20
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum L LDL FC	Kettunen J	22286219	2012	1.32E-20
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum L LDL L	Kettunen J	22286219	2012	4.63E-20
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum L LDL P	Kettunen J	22286219	2012	1.13E-19
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum L LDL PL	Kettunen J	22286219	2012	1.35E-18
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum M HDL LS HDL L	Kettunen J	22286219	2012	7.82E-13
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum M LDL C	Kettunen J	22286219	2012	4.05E-23
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum M LDL CE	Kettunen J	22286219	2012	8.41E-22
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum M LDL CM LDL PL	Kettunen J	22286219	2012	3.41E-25
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum M LDL L	Kettunen J	22286219	2012	7.77E-23
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum M LDL P	Kettunen J	22286219	2012	2.64E-22
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum M LDL PL	Kettunen J	22286219	2012	5.68E-19
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum Serum C	Kettunen J	22286219	2012	1.28E-12
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum S LDL C	Kettunen J	22286219	2012	1.52E-23
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum S LDL L	Kettunen J	22286219	2012	3.37E-23
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum S LDL P	Kettunen J	22286219	2012	4.09E-21
rs429358-C	APOE	rs7256200	chr19:45415935	0.751	Serum Tot C	Kettunen J	22286219	2012	2.05E-12
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	6.83E-08
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	8.83E-07
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Age-related macular degeneration	Fritsche L	23455636	2013	2.80E-13
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Geographic atrophy	Fritsche L	23455636	2013	3.72E-06
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Neovascularization	Fritsche L	23455636	2013	5.17E-08
rs429358-C	APOE	rs6857	chr19:45392254	0.69	BMI	GIANT	25673413	2015	1.30E-04
rs429358-C	APOE	rs6857	chr19:45392254	0.69	BMI	GIANT	25673413	2015	1.03E-04
rs429358-C	APOE	rs6857	chr19:45392254	0.69	BMI in females	GIANT	25673413	2015	1.68E-05
rs429358-C	APOE	rs6857	chr19:45392254	0.69	BMI in females greater than 50 years of age	GIANT	26426971	2015	6.10E-11
rs429358-C	APOE	rs6857	chr19:45392254	0.69	BMI in males greater than 50 years of age	GIANT	26426971	2015	4.80E-04
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Waist circumference	GIANT	25673412	2015	8.30E-05
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Waist circumference	GIANT	25673412	2015	1.20E-04
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Waist circumference in females	GIANT	23754948	2013	7.60E-04
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Waist circumference in females	GIANT	25673412	2015	3.10E-05
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Waist hip ratio	GIANT	25673412	2015	1.70E-05
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Waist hip ratio	GIANT	25673412	2015	1.30E-05
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Waist hip ratio adjusted for BMI	GIANT	25673412	2015	7.80E-05
rs429358-C	APOE	rs6857	chr19:45392254	0.69	tio adjusted for BMI in females greater than 50	GIANT	26426971	2015	5.80E-04
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Waist hip ratio in females	GIANT	23754948	2013	9.50E-04
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Waist hip ratio in females	GIANT	25673412	2015	9.00E-05
rs429358-C	APOE	rs6857	chr19:45392254	0.69	HDL	GLGC	20686565	2010	5.51E-18

rs429358-C	APOE	rs6857	chr19:45392254	0.69	HDL	GLGC	24097068	2013	2.63E-17
rs429358-C	APOE	rs6857	chr19:45392254	0.69	LDL	GLGC	20686565	2010	1.62E-110
rs429358-C	APOE	rs6857	chr19:45392254	0.69	LDL	GLGC	24097068	2013	5.12E-110
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Total cholesterol	GLGC	20686565	2010	6.13E-86
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Total cholesterol	GLGC	24097068	2013	1.70E-86
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Triglycerides	GLGC	20686565	2010	4.28E-21
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Triglycerides	GLGC	24097068	2013	4.55E-19
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Alzheimers disease	IGAP	24162737	2013	2.50e-575
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Body fat percentage	Lu Y	26833246	2016	6.84E-09
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Cerebral amyloid angiopathy	Beecham GW	25188341	2014	3.00E-21
rs429358-C	APOE	rs6857	chr19:45392254	0.69	a and core Alzheimers disease neuropathologic	Beecham GW	25188341	2014	3.00E-38
rs429358-C	APOE	rs6857	chr19:45392254	0.69	a and core Alzheimers disease neuropathologic	Beecham GW	25188341	2014	2.00E-62
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Neuritic plaque	Beecham GW	25188341	2014	2.00E-27
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Neuritic plaque	Beecham GW	25188341	2014	3.00E-47
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Neurofibrillary tangles	Beecham GW	25188341	2014	5.00E-47
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Neurofibrillary tangles	Beecham GW	25188341	2014	5.00E-44
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Verbal declarative memory	Debette S	25648963	2014	4.00E-13
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Frontotemporal dementia	Ferrari R	26154020	2015	8.00E-06
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Age related macular degeneration	Holliday EG	23326517	2013	1.00E-06
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Alzheimer Disease	Kamboh MI	22005931	2011	2.00E-10
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Alzheimers disease biomarkers	Ramanan VK	23419831	2013	1.00E-10
rs429358-C	APOE	rs6857	chr19:45392254	0.69	HDL cholesterol	Asselbergs	23063622	2012	4.15E-07
rs429358-C	APOE	rs6857	chr19:45392254	0.69	LDL cholesterol	Asselbergs	23063622	2012	3.71E-10
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Total cholesterol	Asselbergs	23063622	2012	1.49E-11
rs429358-C	APOE	rs6857	chr19:45392254	0.69	LDL cholesterol	Barber M	20339536	2010	1.47E-05
rs429358-C	APOE	rs6857	chr19:45392254	0.69	LDL cholesterol change with statins	Barber M	20339536	2010	1.50E-05
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Total cholesterol	Barber M	20339536	2010	5.62E-04
rs429358-C	APOE	rs6857	chr19:45392254	0.69	LDL cholesterol response to statins	Deshmukh HA	22368281	2012	5.61E-08
rs429358-C	APOE	rs6857	chr19:45392254	0.69	erol response to statins first post treatment LDL	Deshmukh HA	22368281	2012	5.89E-06
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Advanced age related macular degeneration	Fritsche L	23455636	2013	2.80E-13
rs429358-C	APOE	rs6857	chr19:45392254	0.69	ted macular degeneration choroidal neovascula	Fritsche L	23455636	2013	5.17E-08
rs429358-C	APOE	rs6857	chr19:45392254	0.69	d age related macular degeneration geographic	Fritsche L	23455636	2013	3.72E-06
rs429358-C	APOE	rs6857	chr19:45392254	0.69	HDL cholesterol	GLGC	20686565	2010	5.51E-18
rs429358-C	APOE	rs6857	chr19:45392254	0.69	LDL cholesterol	GLGC	20686565	2010	1.62E-110
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Total cholesterol	GLGC	20686565	2010	6.13E-86
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Triglycerides	GLGC	20686565	2010	4.28E-21
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Lp PLA2 activity	Grallert H	22003152	2011	1.43E-15
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Age related macular degeneration	Holliday EG	23326517	2013	9.70E-07
rs429358-C	APOE	rs6857	chr19:45392254	0.69	ychotic symptoms Alzheimers disease with psyc	Hollingworth P	22005930	2011	1.25E-51
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Alzheimers disease age of onset	Kamboh MI	22005931	2011	4.85E-15
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Late onset Alzheimers disease	Kamboh MI	22832961	2012	4.64E-134
rs429358-C	APOE	rs6857	chr19:45392254	0.69	HDL cholesterol	Kathiresan S	19060906	2008	1.12E-04
rs429358-C	APOE	rs6857	chr19:45392254	0.69	LDL cholesterol	Kathiresan S	19060906	2008	6.78E-18
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Late onset Alzheimers disease	Logue MW	22159054	2011	1.49E-108
rs429358-C	APOE	rs6857	chr19:45392254	0.69	erebral volume white matter hyperintensities in	Melville SA	22745009	2012	9.41E-06
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Late onset Alzheimers disease	Naj AC	21460841	2011	981762945158e

rs429358-C	APOE	rs6857	chr19:45392254	0.69	Parkinsons disease	Pankratz N	22451204	2012	5.92E-05
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Cortical amyloid beta load	Ramanan VK	23419831	2013	1.06E-10
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Alzheimers disease	Seshadri S	20460622	2010	1.00E-153
rs429358-C	APOE	rs6857	chr19:45392254	0.69	Alzheimers disease	Sherva	21098978	2010	2.60E-44
rs429358-C	APOE	rs6857	chr19:45392254	0.69	LDL cholesterol	Willer CJ	18193043	2008	5.50E-22
rs429358-C	APOE	rs12721051	chr19:45422160	0.686	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	1.98E-10
rs429358-C	APOE	rs12721051	chr19:45422160	0.686	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	8.26E-08
rs429358-C	APOE	rs12721051	chr19:45422160	0.686	Alzheimers disease	IGAP	24162737	2013	7.79e-482
rs429358-C	APOE	rs56131196	chr19:45422846	0.686	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	8.24E-11
rs429358-C	APOE	rs56131196	chr19:45422846	0.686	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	3.91E-08
rs429358-C	APOE	rs56131196	chr19:45422846	0.686	HDL	GLGC	24097068	2013	4.40E-10
rs429358-C	APOE	rs56131196	chr19:45422846	0.686	LDL	GLGC	24097068	2013	4.85E-139
rs429358-C	APOE	rs56131196	chr19:45422846	0.686	Total cholesterol	GLGC	24097068	2013	8.55E-103
rs429358-C	APOE	rs56131196	chr19:45422846	0.686	Triglycerides	GLGC	24097068	2013	3.46E-08
rs429358-C	APOE	rs56131196	chr19:45422846	0.686	Alzheimers disease	IGAP	24162737	2013	1.96e-454
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Coronary artery disease	CARDIoGRAM	21378990	2011	2.14E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	7.07E-11
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	4.47E-08
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Type II diabetes	DIAGRAM	24509480	2014	2.00E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Age-related macular degeneration	Fritsche L	23455636	2013	3.16E-15
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Geographic atrophy	Fritsche L	23455636	2013	1.90E-09
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Neovascularization	Fritsche L	23455636	2013	2.78E-08
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	BMI	GIANT	25673413	2015	5.01E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	BMI	GIANT	25673413	2015	4.56E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	BMI in females	GIANT	25673413	2015	3.58E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	BMI in females greater than 50 years of age	GIANT	26426971	2015	5.30E-10
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	BMI in males greater than 50 years of age	GIANT	26426971	2015	7.70E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Waist circumference	GIANT	25673412	2015	4.50E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Waist circumference	GIANT	25673412	2015	4.30E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Waist circumference in females	GIANT	25673412	2015	7.70E-05
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Waist hip ratio	GIANT	25673412	2015	7.60E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Waist hip ratio	GIANT	25673412	2015	4.90E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Waist hip ratio adjusted for BMI	GIANT	25673412	2015	1.80E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	tio adjusted for BMI in females greater than 50	GIANT	26426971	2015	3.40E-05
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Waist hip ratio in females	GIANT	23754948	2013	9.02E-05
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Waist hip ratio in females	GIANT	25673412	2015	2.40E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	HDL	GLGC	20686565	2010	4.40E-21
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	HDL	GLGC	24097068	2013	1.72E-21
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL	GLGC	20686565	2010	8.72E-147
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL	GLGC	24097068	2013	1.51E-178
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol	GLGC	20686565	2010	5.20E-111
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol	GLGC	24097068	2013	1.14E-149
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides	GLGC	20686565	2010	5.44E-22
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides	GLGC	24097068	2013	1.55E-14
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimers disease	IGAP	24162737	2013	1.67e-396
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Body fat percentage	Lu Y	26833246	2016	3.92E-05

rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Fasting glucose	MAGIC	22885924	2012	3.07E-04
rs429358-C	APOE	rs56131196	chr19:45422846	0.686	Alzheimers disease biomarkers	Ramanan VK	23419831	2013	4.00E-12
rs429358-C	APOE	rs56131196	chr19:45422846	0.686	Cortical amyloid beta load	Ramanan VK	23419831	2013	4.06E-12
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol LDL	Burkhardt R	18802019	2008	2.00E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Burkhardt R	18802019	2008	2.00E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimer Disease	Coon KD	17474819	2007	1.00E-39
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimers disease late onset	Coon KD	17474819	2007	1.00E-39
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Verbal declarative memory	Debette S	25648963	2014	6.00E-13
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Verbal declarative memory	Debette S	25648963	2014	1.00E-16
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Verbal declarative memory	Debette S	25648963	2014	2.00E-12
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Longevity 85 years and older	Deelen J	24688116	2014	2.00E-26
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Longevity 90 years and older	Deelen J	24688116	2014	3.00E-36
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C Reactive Protein	Dehghan A	21300955	2011	9.00E-139
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C reactive protein levels	Dehghan A	21300955	2011	9.00E-139
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cognitive decline	De Jager PL	22054870	2011	4.00E-27
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Psychomotor Performance	De Jager PL	22054870	2011	4.00E-27
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C reactive protein	Elliott P	19567438	2009	5.00E-27
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C Reactive Protein	Elliott P	19567438	2009	5.00E-27
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Age related macular degeneration	Fritsche L	23455636	2013	2.00E-20
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol	GLGC	20686565	2010	5.00E-111
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol HDL	GLGC	20686565	2010	4.00E-21
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol LDL	GLGC	20686565	2010	9.00E-147
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol total	GLGC	20686565	2010	5.00E-111
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol total	GLGC	24097068	2013	1.00E-149
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	HDL cholesterol	GLGC	20686565	2010	4.00E-21
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	HDL cholesterol	GLGC	24097068	2013	2.00E-21
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	GLGC	20686565	2010	9.00E-147
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	GLGC	24097068	2013	2.00E-178
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	1 Alkyl 2 acetylglycerophosphocholine Esterase	Grallert H	22003152	2011	5.00E-30
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	rotein associated phospholipase A2 activity and	Grallert H	22003152	2011	5.00E-30
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimer Disease	Kamboh MI	22005931	2011	1.00E-12
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimers disease	Kamboh MI	22832961	2012	8.00E-149
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimers disease age of onset	Kamboh MI	22005931	2011	1.00E-12
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol LDL	Kathiresan S	18193044	2008	1.00E-60
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol LDL	Kathiresan S	19060906	2008	4.00E-27
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Kathiresan S	18193044	2008	1.00E-60
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Kathiresan S	19060906	2008	4.00E-27
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Lipid traits	Keller M	24023261	2013	1.00E-14
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimer Disease	Li H	17998437	2008	2.00E-44
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimers disease	Li H	17998437	2008	2.00E-44
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol	Lowe JK	19197348	2009	3.00E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C Reactive Protein	Lowe JK	19197348	2009	2.00E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Quantitative traits	Lowe JK	19197348	2009	3.00E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Quantitative traits	Lowe JK	19197348	2009	5.00E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Quantitative traits	Lowe JK	19197348	2009	2.00E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides	Lowe JK	19197348	2009	5.00E-06

rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Longevity	Nebel A	21740922	2011	2.00E-16
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Longevity	Nebel A	21740922	2011	2.00E-16
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C reactive protein	Okada Y	21196492	2010	3.00E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C Reactive Protein	Okada Y	21196492	2010	3.00E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol LDL	Sandhu MS	18262040	2008	1.00E-20
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Sandhu MS	18262040	2008	1.00E-20
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol LDL	Saxena R	17463246	2007	3.00E-13
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides	Saxena R	17463246	2007	3.00E-13
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	1 Alkyl 2 acetylglycerophosphocholine Esterase	Suchindran S	20442857	2010	6.00E-24
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	rotein associated phospholipase A2 activity and	Suchindran S	20442857	2010	6.00E-24
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol LDL	Waterworth DM	20864672	2010	2.00E-40
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Waterworth DM	20864672	2010	2.00E-40
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimer Disease	Webster JA	17975299	2007	1.00E-39
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimers disease	Webster JA	17975299	2007	1.00E-39
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Cholesterol LDL	Willer CJ	18193043	2008	3.00E-43
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Willer CJ	18193043	2008	3.00E-43
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	HDL cholesterol	Asselbergs	23063622	2012	3.87E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Asselbergs	23063622	2012	2.54E-12
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol	Asselbergs	23063622	2012	3.13E-12
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides ln	Asselbergs	23063622	2012	2.95E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	olic syndrome domains Atherogenic Dyslipidem	Avery	22022282	2011	1.00E-31
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Metabolic syndrome domains Central obesity	Avery	22022282	2011	1.20E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	tabolic syndrome domains Elevated plasma gluc	Avery	22022282	2011	8.70E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	letabolic syndrome domains Multivariate analys	Avery	22022282	2011	1.70E-57
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	bolic syndrome domains Vascular Inflammation	Avery	22022282	2011	5.00E-12
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Barber M	20339536	2010	6.29E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol change with statins	Barber M	20339536	2010	6.30E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol	Barber M	20339536	2010	3.37E-05
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol change with statins	Barber M	20339536	2010	1.60E-05
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Burkhardt R	18802019	2008	1.89E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	protein associated phospholipase A2 activity Lp	Chu AY	23118302	2012	9.20E-21
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Sporadic late onset Alzheimers disease	Coon KD	17474819	2007	1.06E-39
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C reactive protein CRP	Dehghan A	21300955	2011	8.80E-139
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimers disease	De Jager PL	22054870	2011	9.42E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Rate of age related cognitive decline	De Jager PL	22054870	2011	3.74E-27
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Demirkan A	22359512	2012	2.60E-09
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol response to statins	Deshmukh HA	22368281	2012	3.70E-12
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	erol response to statins first post treatment LDL	Deshmukh HA	22368281	2012	1.16E-09
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C reactive protein CRP	Elliott P	19567438	2009	4.50E-27
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	HDL cholesterol	Elliott P	19567438	2009	1.60E-08
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Elliott P	19567438	2009	3.50E-20
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol	Elliott P	19567438	2009	7.50E-17
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides	Elliott P	19567438	2009	7.00E-10
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Advanced age related macular degeneration	Fritsche L	23455636	2013	2.00E-20
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	ted macular degeneration choroidal neovascula	Fritsche L	23455636	2013	2.78E-08
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	d age related macular degeneration geographic	Fritsche L	23455636	2013	1.90E-09

rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Coronary artery disease CAD	GLGC	20686565	2010	7.00E-05
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	HDL cholesterol	GLGC	20686565	2010	2.30E-22
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	GLGC	20686565	2010	1.10E-152
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol	GLGC	20686565	2010	2.70E-116
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol females	GLGC	20686565	2010	1.00E-72
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol males	GLGC	20686565	2010	6.00E-20
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides	GLGC	20686565	2010	5.44E-22
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	ary heart disease CHD or coronary artery diseas	Grallert H	22003152	2011	2.10E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Lp PLA2 activity	Grallert H	22003152	2011	4.90E-30
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Lp PLA2 mass	Grallert H	22003152	2011	4.30E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Waist circumference	Heard Costa NL	19557197	2009	3.60E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Waist hip ratio	Heid IM	20935629	2010	8.50E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	APOB apolipoprotein B	Hopewell	23100282	2012	3.10E-32
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	oprotein B response after 40mg daily simvastat	Hopewell	23100282	2012	5.70E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Hopewell	23100282	2012	2.10E-38
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	esterol response after 40mg daily simvastatin tr	Hopewell	23100282	2012	6.40E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Kamatani Y	20139978	2010	3.99E-05
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimers disease age of onset	Kamboh MI	22005931	2011	4.14E-14
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Late onset Alzheimers disease	Kamboh MI	22832961	2012	7.91E-149
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	APOB apolipoprotein B	Kathiresan S	19060906	2008	6.50E-05
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	APOE apolipoprotein E	Kathiresan S	19060906	2008	3.30E-08
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Kathiresan S	18193044	2008	1.00E-60
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Kathiresan S	19060906	2008	2.38E-31
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides	Kathiresan S	19060906	2008	9.92E-04
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Lettre G	21347282	2011	1.00E-60
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimers disease	Li H	17998437	2008	2.26E-44
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Late onset Alzheimers disease	Logue MW	22159054	2011	1.07E-144
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C reactive protein CRP	Lowe JK	19197348	2009	1.60E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Lowe JK	19197348	2009	1.90E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol	Lowe JK	19197348	2009	3.40E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides	Lowe JK	19197348	2009	5.00E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	HDL cholesterol	Middelberg RP	21943158	2011	1.50E-08
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Middelberg RP	21943158	2011	4.30E-14
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides	Middelberg RP	21943158	2011	3.60E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	High sensitivity C reactive protein CRP	Naitza S	22291609	2012	7.13E-11
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Late onset Alzheimers disease	Naj AC	21460841	2011	1.00E-300
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Longevity	Nebel A	21740922	2011	1.60E-10
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Serum C reactive protein	Okada Y	21196492	2010	2.90E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	C reactive protein CRP	Reiner AP	22939635	2012	1.80E-05
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol in serum	Sandhu MS	18262040	2008	1.20E-20
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	APOB apolipoprotein B	Saxena R	17463246	2007	2.72E-05
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Saxena R	17463246	2007	3.40E-13
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Total cholesterol	Saxena R	17463246	2007	9.77E-12
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Alzheimers disease	Seshadri S	20460622	2010	1.60E-166
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	APOB apolipoprotein B	Suchindran S	20442857	2010	5.60E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	APOE apolipoprotein E	Suchindran S	20442857	2010	8.10E-31

rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Suchindran S	20442857	2010	3.30E-11
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Lp PLA2 activity	Suchindran S	20442857	2010	5.86E-24
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol in serum	Wallace C	18179892	2008	3.57E-14
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Coronary artery disease CAD	Waterworth DM	20864672	2010	1.50E-06
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	HDL cholesterol	Waterworth DM	20864672	2010	2.00E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Waterworth DM	20864672	2010	1.70E-40
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	Triglycerides	Waterworth DM	20864672	2010	5.50E-07
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	LDL cholesterol	Willer CJ	18193043	2008	3.00E-43
rs429358-C	APOE	rs4420638	chr19:45422946	0.686	onary artery disease CAD combined control data	WTCCC	17554300	2007	1.68E-04
rs429358-C	APOE	rs814573	chr19:45424351	0.662	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	1.11E-05
rs429358-C	APOE	rs814573	chr19:45424351	0.662	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	6.25E-04
rs429358-C	APOE	rs59007384	chr19:45396665	0.64	Coronary artery disease	CARDIoGRAMplusC4D	26343387	2015	5.97E-04
rs429358-C	APOE	rs59007384	chr19:45396665	0.64	Myocardial infarction	CARDIoGRAMplusC4D	26343387	2015	5.19E-04
rs429358-C	APOE	rs59007384	chr19:45396665	0.64	Alzheimers disease	IGAP	24162737	2013	1.97e-486
rs429358-C	APOE	rs59007384	chr19:45396665	0.64	Alzheimers disease biomarkers	Ramanan VK	23419831	2013	7.00E-09
rs429358-C	APOE	rs59007384	chr19:45396665	0.64	Cognitive ageing	Davies G	23207651	2012	6.26E-07
rs429358-C	APOE	rs59007384	chr19:45396665	0.64	Cognitive ageing females	Davies G	23207651	2012	4.06E-07
rs429358-C	APOE	rs59007384	chr19:45396665	0.64	Cortical amyloid beta load	Ramanan VK	23419831	2013	6.70E-09
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Alzheimers disease	IGAP	24162737	2013	2.09e-373
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum LDL C	Kettunen J	22286219	2012	1.18E-13
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum L LDL C	Kettunen J	22286219	2012	5.21E-12
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum L LDL CE	Kettunen J	22286219	2012	1.04E-11
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum L LDL FC	Kettunen J	22286219	2012	8.88E-12
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum L LDL L	Kettunen J	22286219	2012	8.78E-12
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum L LDL P	Kettunen J	22286219	2012	1.31E-11
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum L LDL PL	Kettunen J	22286219	2012	7.07E-11
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum M LDL C	Kettunen J	22286219	2012	2.41E-14
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum M LDL CE	Kettunen J	22286219	2012	1.76E-13
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum M LDL CM LDL PL	Kettunen J	22286219	2012	1.82E-15
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum M LDL L	Kettunen J	22286219	2012	2.85E-14
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum M LDL P	Kettunen J	22286219	2012	5.26E-14
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum M LDL PL	Kettunen J	22286219	2012	7.09E-12
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum S LDL C	Kettunen J	22286219	2012	4.78E-15
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum S LDL L	Kettunen J	22286219	2012	3.41E-15
rs429358-C	APOE	rs483082	chr19:45416178	0.634	Serum S LDL P	Kettunen J	22286219	2012	7.47E-14
rs429358-C	APOE	rs5117	chr19:45418790	0.624	Alzheimers disease	IGAP	24162737	2013	8.59e-390

Supplementary Data 5 | Genetic Correlations with Mortality a measured using LDHub and LDScore regression

Meaningful and significant

Trait	rg	se	p	PMID
Coronary arte	0.6578	0.0457	<1.00E-07	26343387
Cigarettes sm	0.5793	0.1078	1.00E-07	20418890
Lung adenoca	0.4123	0.1294	0.0014	27488534
Type 2 Diabe	0.4091	0.0613	<1.00E-07	22885922
HOMA-IR	0.3999	0.0963	0.0000327	20081858
Body fat	0.3988	0.055	<1.00E-07	26833246
Lung cancer	0.3952	0.0742	0.0000001	27488534
Leptin_not_a	0.3942	0.0871	0.000006	26833098
Urinary albur	0.3908	0.0951	0.0000396	26631737
Lung cancer (	0.3843	0.0858	0.0000075	24880342
SBP	0.3776	0.0522	<1.00E-07	27618452
Obesity class	0.3683	0.0447	<1.00E-07	23563607
Waist circum	0.3627	0.0411	<1.00E-07	25673412
Fasting insuli	0.3589	0.0705	0.0000004	22581228
CRP	0.3547	0.0712	0.0000006	21300955
Waist-to-hip	0.3545	0.0405	<1.00E-07	25673412
DBP	0.3526	0.0528	<1.00E-07	27618452
Overweight	0.3477	0.0451	<1.00E-07	23563607
Obesity class	0.3428	0.0489	<1.00E-07	23563607
Fasting gluco	0.3374	0.073	0.0000038	22581228
Urinary albur	0.3274	0.0955	0.0006	26631737
Body mass in	0.303	0.0419	<1.00E-07	20935630
Childhood ob	0.3005	0.0645	0.0000032	22484627
Urate	0.2925	0.0784	0.0002	23263486
Hip circumfer	0.2793	0.0453	<1.00E-07	25673412
Triglycerides	0.2741	0.0451	<1.00E-07	20686565
Primary biliar	0.2731	0.0803	0.0007	26394269
Depressive sy	0.2643	0.0518	0.0000003	27089181
HbA1C	0.2572	0.0797	0.0013	20858683
Obesity class	0.2562	0.0698	0.0002	23563607
Extreme bmi	0.2537	0.0634	0.0000624	23563607
Extreme wais	0.2506	0.0856	0.0034	23563607
Rheumatoid /	0.1725	0.053	0.0011	24390342
Breast Cance	0.1708	0.0437	0.0000931	25751625
Age at Menop	-0.1523	0.052	0.0034	26414677
Subjective we	-0.1574	0.0531	0.003	27089181
Birth weight	-0.2063	0.0405	0.0000003	27680694
Child birth we	-0.2475	0.0846	0.0034	23202124
HDL choleste	-0.2481	0.049	0.0000004	20686565
Neo-openness	-0.3728	0.1178	0.0015	21173776
College comp	-0.455	0.057	<1.00E-07	23722424
Age of first bi	-0.4562	0.0425	<1.00E-07	27798627

Years of scho	-0.4691	0.0321	<1.00E-07	27225129
Years of scho	-0.4732	0.0505	<1.00E-07	25201988
Years of scho	-0.4739	0.0518	<1.00E-07	23722424
Former vs Cu	-0.6446	0.0997	<1.00E-07	20418890

Certainly non-meaningful

Trait	rg	se	p	PMID
Schizophrenia	0.0666	0.0364	0.0669	25056061
Platelet coun	0.029	0.0512	0.571	22139419
Bipolar disorc	0.0215	0.0585	0.7134	21926972
Femoral Neck	0.0209	0.0562	0.7096	26367794
Extreme heig	0.0164	0.0489	0.7376	23563607
Lumbar Spine	-0.0155	0.0555	0.7806	26367794
Lumbar spine	-0.018	0.0545	0.7413	26367794
Femoral neck	-0.0251	0.0476	0.5972	26367794
Autism spect	-0.0289	0.061	0.6351	NA
Height 2010	-0.029	0.0354	0.4136	20881960
Serum creatir	-0.0293	0.047	0.5335	26831199
Serum creatir	-0.0408	0.047	0.3857	26831199

Unknown significance

Trait	rg	se	p	PMID
Lung cancer (	0.3164	0.1396	0.0234	24880342
Squamous ce	0.308	0.117	0.0085	27488534
Attention def	0.3062	0.1213	0.0116	20732625
Multiple sclei	0.2371	0.1442	0.1002	21833088
Neuroticism	0.2015	0.0904	0.0258	27089181
Fasting proin	0.2002	0.1063	0.0597	20081858
Leptin_adjBM	0.1878	0.0853	0.0277	26833098
Crohns disea	0.1541	0.0577	0.0076	26192919
Total Cholest	0.1489	0.0579	0.0102	20686565
Asthma	0.1484	0.0862	0.0851	17611496
Mean Caudat	0.1473	0.0756	0.0515	25607358
Neuroticism	0.1358	0.0428	0.0015	27089181
LDL cholester	0.1332	0.0668	0.0461	20686565
HOMA-B	0.1278	0.0787	0.1043	20081858
Height; Fema	0.1242	0.0591	0.0357	23449627
Inflammatory	0.1239	0.0533	0.02	26192919
Serumurate c	0.1227	0.0885	0.1655	25811787
Mean platele	0.1177	0.0618	0.057	22139419
Systemic lupu	0.1097	0.0653	0.0929	26502338
Mean Pallidu	0.1077	0.0893	0.2277	25607358
Heart rate	0.107	0.0554	0.0535	23583979
2hr glucose a	0.1031	0.106	0.3306	20081857
Eczema	0.101	0.0842	0.2302	26482879
Chronotype	0.0948	0.0455	0.0371	27494321

Number of ch	0.0911	0.052	0.0796	27798627
Chronic Kidne	0.0862	0.0978	0.3777	26831199
ICV	0.0832	0.083	0.316	25607358
Ferritin	0.0817	0.1061	0.4415	25352340
PGC cross-dis	0.08	0.05	0.1095	23453885
Major depres	0.0723	0.0744	0.3311	22472876
Transferrin	0.0658	0.0837	0.4319	25352340
Alzheimers di	0.0542	0.0911	0.5524	24162737
Ulcerative co	0.0486	0.0598	0.4163	26192919
Mean Accum	0.0405	0.1313	0.7578	25607358
Forearm Bon	0.0292	0.1307	0.8235	26367794
Amyotrophic	0.0137	0.1131	0.9032	27455348
Celiac disease	-0.0283	0.0814	0.7279	20190752
Sitting height	-0.0347	0.0692	0.6157	25865494
Mean Hippoc	-0.0348	0.1114	0.755	25607358
Child birth le	-0.0651	0.0764	0.3944	25281659
Mean Putam	-0.0703	0.0586	0.2305	25607358
Difference in	-0.0741	0.0764	0.3327	23449627
Infant head c	-0.0851	0.1024	0.4057	22504419
Anorexia Ner	-0.094	0.0484	0.0522	24514567
Mean Thalam	-0.0975	0.1067	0.361	25607358
Age of smoki	-0.1123	0.1147	0.3274	20418890
Sleep duratio	-0.1353	0.0574	0.0184	27494321
Adiponectin	-0.1361	0.0768	0.0762	22479202
Parkinsons di	-0.1438	0.065	0.0269	19915575
Age at Menar	-0.1455	0.0379	0.0001	25231870
Serum cystat	-0.1896	0.0985	0.0542	26831199
Neo-conscier	-0.2096	0.1371	0.1262	21173776
Difference in	-0.2342	0.0927	0.0115	23449627
Childhood IQ	-0.2669	0.0977	0.0063	23358156
Ever vs never	NA	NA	NA	20418890

and 113 traits

Supplementary Data 6 | Studies used for M

Author	Category	Consortium	N cases	N controls	N SNPs	PMID
Dastani Z	Risk factor	ADIPOGen	NA	NA	2675209	22479202
Locke AE	Risk factor	GIANT	NA	NA	2555511	25673413
Nikpay	Disease	DIoGRAMplus	60801	123504	9455779	26343387
Benyamin B	Risk factor	SSGAC	NA	NA	1380159	23358156
Ripke S	Disease	PGC	35476	46839	9444231	25056061
Mahajan A	Disease	DIAGRAM	26488	83964	2915012	24509480
van der Valk R	Risk factor	EGG	NA	NA	2201972	25281659
Liu	Disease	IIBDGC	5956	14927	12276506	26192919
Liu	Disease	IIBDGC	12882	21770	12716084	26192919
Liu	Disease	IIBDGC	6968	20464	12255197	26192919
Moffatt MF	Disease	GABRIEL	10365	16110	546183	20860503
Boraska V	Disease	GCAN	2907	14860	1149254	24514567
Shungin D	Risk factor	GIANT	NA	NA	2559739	25673412
Shungin D	Risk factor	GIANT	NA	NA	2547573	25673412
Shungin D	Risk factor	GIANT	NA	NA	2560782	25673412
Berndt SI	Risk factor	GIANT	7962	8106	1984814	23563607
Berndt SI	Risk factor	GIANT	8097	8099	1966557	23563607
Berndt SI	Risk factor	GIANT	4774	5481	1939901	23563607
Wood AR	Risk factor	GIANT	NA	NA	2550859	25282103
Berndt SI	Risk factor	GIANT	32858	65839	2380428	23563607
Berndt SI	Risk factor	GIANT	9889	62657	2331456	23563607
Berndt SI	Risk factor	GIANT	2896	47468	2250779	23563607
Berndt SI	Risk factor	GIANT	93015	65840	2435045	23563607
de Moor MH	Risk factor	GPC	NA	NA	2305462	21173776
de Moor MH	Risk factor	GPC	NA	NA	2305683	21173776
de Moor MH	Risk factor	GPC	NA	NA	2305823	21173776
de Moor MH	Risk factor	GPC	NA	NA	2305739	21173776
de Moor MH	Risk factor	GPC	NA	NA	2305641	21173776
de Moor	Risk factor	GPC	NA	NA	6949615	25993607
Lambert	Disease	IGAP	25580	48466	11633	24162737
Willer CJ	Risk factor	GLGC	NA	NA	2447442	24097068
Willer CJ	Risk factor	GLGC	NA	NA	2437752	24097068
Willer CJ	Risk factor	GLGC	NA	NA	2446982	24097068
Willer CJ	Risk factor	GLGC	NA	NA	2439433	24097068
Soranzo N	Risk factor	MAGIC	NA	NA	2576680	20858683
Dupuis J	Risk factor	MAGIC	NA	NA	2456946	20081858
Dupuis J	Risk factor	MAGIC	NA	NA	2458074	20081858
Manning AK	Risk factor	MAGIC	NA	NA	2635762	22581228
Scott	Risk factor	MAGIC	NA	NA	64484	22885924
Nikpay	Disease	DIoGRAMplus	43676	128199	9289492	26343387
Sklar P	Disease	PGC	7481	9250	108835	21926972

Sullivan	Disease	PGC	9240	9519	123041	22472876
NA	Disease	PGC	4949	5314	9499590	NA
Mueller	Disease	NA	1487	1592	350155	16775037
imon-Sanchez	Disease	NA	1713	3978	453218	19915575
Olfson	Risk factor	NA	1897	1932	917030	22978509
Matarin M	Disease	NA	249	268	393465	17434096
ımundadottir	Disease	PanScan1	1896	1939	521863	19648918
Ciampa J	Disease	NA	1175	1100	184483	21372204
Ehret GB	Risk factor	ICBP	NA	NA	2650287	21909115
Wain LV	Risk factor	ICBP	NA	NA	2585510	21909110
Wain LV	Risk factor	ICBP	NA	NA	2585158	21909110
Rietveld CA	Risk factor	SSGAC	20044	75383	2321511	23722424
Kettunen	Metabolites	NA	NA	NA	11760646	27005778
Kettunen	Metabolites	NA	NA	NA	11813266	27005778
Kettunen	Metabolites	NA	NA	NA	12087816	27005778
Kettunen	Metabolites	NA	NA	NA	11401623	27005778
Kettunen	Metabolites	NA	NA	NA	11398837	27005778
Kettunen	Metabolites	NA	NA	NA	11412520	27005778
Kettunen	Metabolites	NA	NA	NA	12052259	27005778
Kettunen	Metabolites	NA	NA	NA	11412092	27005778
Kettunen	Metabolites	NA	NA	NA	11807298	27005778
Furberg	Risk factor	TAG	NA	NA	2459119	20418890
Furberg	Risk factor	TAG	41969	32066	2455847	20418890
Furberg	Risk factor	TAG	23554	18415	2456555	20418890
Furberg	Risk factor	TAG	NA	NA	2457546	20418890
Wang Y	Disease	ILCCO	3442	14894	8881354	24880342
Wang Y	Disease	ILCCO	11348	15861	8945893	24880342
Wang Y	Disease	ILCCO	3275	15038	8893750	24880342
Wade TD	Disease	NA	151	2291	11846513	23568457
Pattaro	Disease	CKDGen	12385	104780	2191877	26831199
Lu	Risk factor	NA	NA	NA	3228665	26833246
Okbay	Risk factor	SSGAC	NA	NA	6524475	27089181
Okbay	Risk factor	SSGAC	NA	NA	8146841	27225129
ɔel<U+00E4>ı	Risk factor	NA	NA	NA	2474010	26833098
Day	Risk factor	ReproGen	NA	NA	2418696	26414677
Manichaikul A	Risk factor	MESA	NA	NA	2968584	24383474
Okbay	Risk factor	SSGAC	NA	NA	2268675	27089181
Beecham	Disease	IMSGC	14498	24091	156632	24076602
Pappa	Disease	EAGLE	NA	NA	2188529	26087016
Middeldorp	Disease	EAGLE	NA	NA	5837347	27663945
<U+00F6>ttge	Risk factor	GUGC	NA	NA	2450548	23263486
den Hoed M	Risk factor	gene consorti	NA	NA	2516790	23583979
Cha	Disease	NA	41	866	425707	22318345
Trynka	Disease	NA	12041	12228	38037	22057235
Kohler A	Disease	NA	649	431	572028	23894154
Horikoshi	Risk factor	NA	NA	NA	22434434	27680694

van Rheenen	Disease	Project MinE	12577	23475	8709432	27455348
Jones	Risk factor	UK Biobank	NA	NA	16761226	27494321
Pilling	Risk factor	UK Biobank	NA	NA	9583643	27015805
Perry JR	Risk factor	ReproGen	NA	NA	2441816	25231870
Bradfield JP	Risk factor	EGG	5530	8318	2442739	22484627
Pattaro	Risk factor	CKDGen	NA	NA	2198208	26831199
Pattaro	Risk factor	CKDGen	NA	NA	2197556	26831199
Teumer	Risk factor	CKDGen	NA	NA	2190189	26631737
Ehret GB	Risk factor	ICBP	NA	NA	2687670	27618452
Ehret GB	Risk factor	ICBP	NA	NA	2687670	27618452
Dehghan A	Risk factor	NA	NA	NA	2508891	21300955
Michailidou K	Disease	BCAC	46,785	42,892	14062810	25751625

MR Study.

Population	Sample size	SD	Sex	Subcategory
Mixed	39883	0.5700	Males and females	Protein
Mixed	339224	4.7700	Males and females	Anthropometric
Mixed	184305	NA	Males and females	Cardiovascular
European	12441	NA	Males and females	Education
Mixed	82315	NA	Males and females	Psychiatric / neurological
Mixed	110452	NA	Males and females	Diabetes
European	28459	1.9600	Males and females	Anthropometric
European	20883	NA	Males and females	utoimmune / inflammato
European	34652	NA	Males and females	utoimmune / inflammato
European	27432	NA	Males and females	utoimmune / inflammato
European	26475	NA	Males and females	utoimmune / inflammato
European	17767	NA	Males and females	Psychiatric / neurological
European	213038	8.4548	Males and females	Anthropometric
Mixed	245746	12.5200	Males and females	Anthropometric
European	212244	0.0761	Males and females	Anthropometric
European	16068	NA	Males and females	Anthropometric
European	16196	NA	Males and females	Anthropometric
European	10255	NA	Males and females	Anthropometric
European	253288	0.0699	Males and females	Anthropometric
European	98697	NA	Males and females	Anthropometric
European	72546	NA	Males and females	Anthropometric
European	50364	NA	Males and females	Anthropometric
European	158855	NA	Males and females	Anthropometric
European	17375	5.3600	Males and females	Personality
European	17375	6.2400	Males and females	Personality
European	17375	6.4900	Males and females	Personality
European	17375	8.2000	Males and females	Personality
European	17375	5.9200	Males and females	Personality
European	160958	NA	Males and females	Psychiatric / neurological
European	74046	NA	Males and females	Psychiatric / neurological
Mixed	187167	15.5102	Males and females	Lipid
Mixed	173082	38.6746	Males and females	Lipid
Mixed	187365	41.7507	Males and females	Lipid
Mixed	177861	90.7242	Males and females	Lipid
European	46368	0.5343	Males and females	Glycemic
European	46186	0.9574	Males and females	Glycemic
European	46186	0.6697	Males and females	Glycemic
European	58074	0.7303	Males and females	Glycemic
European	108557	0.7900	Males and females	Glycemic
Mixed	171875	NA	Males and females	Cardiovascular
European	16731	NA	Males and females	Psychiatric / neurological

European	18759	NA	Males and females	Psychiatric / neurological
European	10263	NA	Males and females	Psychiatric / neurological
European	3079	NA	Males and females	Kidney
European	5691	NA	Males and females	Psychiatric / neurological
Mixed	3829	NA	Males and females	Behavioural
European	517	NA	Males and females	Cardiovascular
European	3835	NA	Males and females	Cancer
European	2275	NA	Males and females	Cancer
European	74064	NA	Males and females	Blood pressure
European	74064	NA	Males and females	Blood pressure
European	74064	NA	Males and females	Blood pressure
European	95427	NA	Males and females	Education
European	20687	NA	Males and females	Protein
European	20690	NA	Males and females	Protein
European	24810	NA	Males and females	Amino acid
European	13544	NA	Males and females	Fatty acid
European	13506	NA	Males and females	Fatty acid
European	13506	NA	Males and females	Fatty acid
European	24679	NA	Males and females	Carbohydrate
European	13505	NA	Males and females	Fatty acid
European	18814	NA	Males and females	Amino acid
European	68028	11.6978	Males and females	Behavioural
European	74035	NA	Males and females	Behavioural
European	41969	NA	Males and females	Behavioural
European	47961	0.3400	Males and females	Behavioural
European	18336	NA	Males and females	Cancer
European	27209	NA	Males and females	Cancer
European	18313	NA	Males and females	Cancer
European	2442	NA	Females	Psychiatric / neurological
Mixed	117165	NA	Males and females	Kidney
European	100716	NA	Males and females	Anthropometric
European	161460	NA	Males and females	Psychiatric / neurological
European	293723	3.7100	Males and females	Education
European	32161	NA	Males and females	Hormone
European	69360	3.9300	Females	Reproductive aging
Mixed	7667	0.7080	Males and females	Lung disease
European	298420	NA	Males and females	Psychiatric / neurological
European	38589	NA	Males and females	utoimmune / inflammato
European	18988	NA	Males and females	Psychiatric / neurological
European	17666	NA	Males and females	Psychiatric / neurological
European	110347	1.3300	Males and females	Other
Mixed	92355	NA	Males and females	Hemodynamic
East Asian	907	NA	Males and females	Cancer
European	24269	NA	Males and females	utoimmune / inflammato
European	1080	NA	Males and females	Cancer
Mixed	153781	NA	Males and females	Anthropometric

European	36052	NA	Males and females	Psychiatric / neurological
European	128266	NA	Males and females	Sleeping
European	75244	NA	Males and females	Aging
European	182416	NA	Females	Reproductive aging
European	13848	NA	Males and females	Anthropometric
Mixed	133814	0.2400	Males and females	Kidney
Mixed	33152	0.2300	Males and females	Kidney
European	54450	0.9600	Males and females	Kidney
European	342415	10.6500	Males and females	Blood pressure
European	342415	18.9000	Males and females	Blood pressure
	82725	1.0780	Males and females	Reactive proteine C
European	89,677	NA	Females	Cancer

Trait	Unit	Year
Adiponectin	ln(mg/dL)	2012
Body mass index	SD (kg/m^2)	2015
Coronary heart disease	log odds	2015
Childhood intelligence	SD	2014
Schizophrenia	log odds	2014
Type 2 diabetes	log odds	2014
Birth length	SD (cm)	2015
Crohn's disease	log odds	2015
Inflammatory bowel disease	log odds	2015
Ulcerative colitis	log odds	2015
Asthma	log odds	2007
Anorexia nervosa	log odds	2014
Hip circumference	SD (cm)	2015
Waist circumference	SD (cm)	2015
Waist-to-hip ratio	SD	2015
Extreme body mass index	log odds	2013
Extreme height	log odds	2013
Extreme waist-to-hip ratio	log odds	2013
Height	SD (m)	2014
Obesity class 1	log odds	2013
Obesity class 2	log odds	2013
Obesity class 3	log odds	2013
Overweight	log odds	2013
Neo-agreeableness	arbitrary score	2012
Neo-conscientiousness	arbitrary score	2012
Neo-extraversion	arbitrary score	2012
Neo-neuroticism	arbitrary score	2012
Neo-openness to experience	arbitrary score	2012
Neuroticism	arbitrary score	2014
Alzheimer's disease	log odds	2013
HDL cholesterol	SD (mg/dL)	2013
LDL cholesterol	SD (mg/dL)	2013
Total cholesterol	SD (mg/dL)	2013
Triglycerides	SD (mg/dL)	2013
HbA1C	%	2010
HOMA-B	log HOMA	2011
HOMA-IR	log HOMA	2011
Fasting glucose	mmol/L	2012
Fasting insulin	log pmol/L	2013
Myocardial infarction	log odds	2015
Bipolar disorder	log odds	2011

Major depressive disorder	log odds	2013
Autism	log odds	2015
Diabetic nephropathy	log odds	2006
Parkinson's disease	log odds	2009
Alcohol dependence	log odds	2012
Ischaemic stroke	log odds	2007
Pancreatic cancer	log odds	2009
Prostate cancer	log odds	2011
Diastolic blood pressure	SD	2011
Pulse pressure	SD	2011
Mean arterial pressure	SD	2011
College completion	log odds	2013
Apolipoprotein A-I	SD	2016
Apolipoprotein B	SD	2016
Creatinine	SD	2016
Omega-3 fatty acids	SD	2016
Omega-6 fatty acids	SD	2016
Omega-9 and saturated fatty acids	SD	2016
Glucose	SD	2016
Total fatty acids	SD	2016
Urea	SD	2016
Cigarettes smoked per day	garettes per d	2010
Ever vs never smoked	log odds	2010
Former vs current smoker	log odds	2010
Age of smoking initiation	log years	2010
Lung adenocarcinoma	log odds	2014
Lung cancer	log odds	2014
Squamous cell lung cancer	log odds	2014
Bulimia nervosa	log odds	2013
Chronic kidney disease	log odds	2015
Body fat	SD	2016
Depressive symptoms	SD	2016
Years of schooling	SD (years)	2016
Leptin	log ng/ml	2016
Age at menopause	years	2015
Percent emphysema	% emphysema	2014
Subjective well being	SD	2016
Multiple sclerosis	log odds	2013
Aggression	NA	2016
ADHD	score	2016
Urate	mg/dl	2013
Heart rate	eats per minu	2013
Gallbladder cancer	log odds	2012
Celiac disease	log odds	2011
Thyroid cancer	log odds	2013
Birth weight	SD	2016

Amyotrophic lateral sclerosis	log odds	2016
Sleep duration	SD	2016
Top 1 % survival	log odds	2016
Age at menarche	years	2014
Childhood obesity	log odds	2012
Serum creatinine (eGFRcrea)	ıin/1.73 m^<ι	2015
Serum cystatin C (eGFRcys)	ıin/1.73 m^<ι	2015
Urinary albumin-to-creatinine ratic	log mg/g	2015
Diastolic blood pressure	mmHg	2016
Sistolic blood pressure	mmHg	2016
CRP	log mg/L	2017
Breast Cancer	log odds	2015